Investigating the expression of genes and proteins in Glioblastoma during hypoxia by Monteiro, Ana Rita Alves Pereira de Ferreira
   
 
 
Ana Rita Alves Pereira de Ferreira Monteiro 
 
 
Investigating the expression of 
genes and proteins in 
Glioblastoma during hypoxia
 
 
 
 
 
 
 
 
 
 
 
 
Biomedical Sciences and Medicine Department 
Year 2017/2018 
 
 
 
 
   
 
 
Ana Rita Alves Pereira de Ferreira Monteiro 
 
  
Investigating the expression of 
genes and proteins in 
Glioblastoma during hypoxia 
 
 
Master in Oncobiology –  
Molecular Mechanisms of Cancer 
 
 
 
Work Supervised by: 
 
 Dr. Patrícia Madureira, Cancer Biology and Progression Laboratory, 
Centre for   Biomedical Research (University of Algarve) and Brain 
Tumour Research Centre of Excellence (University of Portsmouth); 
 
Dr. Ana Teresa Maia, Centre for Biomedical Research and 
Department of Biomedical Sciences and Medicine (University of 
Algarve). 
 
 
 
 
 
 
 
 
Biomedical Sciences and Medicine Department 
Year 2017/2018 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
Investigating the expression of 
genes and proteins in Glioblastoma 
during hypoxia 
 
 
 
Statement of authorship 
I hereby declare that I am the author of this work, which is, to the 
best of my knowledge and belief, original, except as 
acknowledged in the text. Authors and work consulted are 
properly cited in the text and listed in the references in the 
required format. The material has not been previously submitted, 
in whole or in part, for a degree at this or any other university. 
 
 
 
 
_________________________________ 
Signature 
 
   
 
 
 
 
 
 
 
 
 
 
© Copyright: Ana Rita Monteiro 
The University of Algarve has the perpetual right, without 
geographical boundaries, to archive and publicize this work in 
the form of printed copies, in digital form, or by any other 
means known or that may be invented, for the release through 
scientific repositories and to admit its copying and distribution 
for educational or research purposes only, not commercial, as 
long as full credit is given to the author and editor. 
 
 
 
   
 
 
 
   
 
 
I 
Acknowledgements 
I am enormously grateful to my supervisor, Dr. Patrícia Madureira for giving me the 
wonderful opportunity to work in a such amazing lab as the one from the Brain Tumour 
Research Excellence center at University of Portsmouth. I am immensely thankful for 
all the shared knowledge, encouragement and patience, as well the friendship, 
support and warm welcome in Portsmouth. My wish is that future will bring us to work 
together again.  
A big thank you to Dr. Richard Hill who also supervised, helped and taught me during 
the 10 months I spend in the laboratory.  
I would also like to express my profound gratitude to my co-supervisor Dr. Ana Teresa 
Maia, who took time from an incredibly busy schedule to assist me with my 
dissertation. I am truly thankful for the help and attentiveness.  
I am extremely grateful to Professor Geoffrey J. Pilkington and everyone in the Brain 
Tumour Research Excellence center laboratory from University of Portsmouth, for 
accepting me and giving me the chance to learn and grow as a person and a scientist 
in a challenging environment.  
 
A big thanks to all my friends in Portsmouth, particularly Mohsen Seifi, Noor Alabdullah 
and Tarek Zaidieh who gave support and motivation in harder days and who made me 
feel like at home. I am also enormously grateful to my dear friend Diana Leite for all 
the help in the laboratory, as well the friendship, companionship, shared laughs and 
for making my days happier.  
 
I am also immensely grateful to my friends and dear colleagues Juliana Machado and 
Catarina Martins. Thank you for accommodating me in your office, homes and hearts.  
 
A heartfelt gratitude goes to everyone from “Grupeta dos 10 magníficos”, who are 
indeed the best friends in the world. Thank you for these 8 years of friendship and for 
all the encouragement words.  
   
 
 
II 
 
For all the love and caring, I am infinitely grateful to Daniel Duarte who despite being 
miles away from me, kept close at all times. You proved there is no distance for love.  
 
Most importantly, I am eternally grateful to my parents Elisabete Pereira and Samuel 
Monteiro who supported me financially through this opportunity, for being by me side 
at all times and for loving me unconditionally and for making of me what I am today. I 
owe you all my triumphs. Also, a tremendously heartfelt gratitude to by brother Miguel 
Monteiro and sister Joana Monteiro. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Nature is the source of all true knowledge. She has her own logic, her own laws, she has no 
effect without cause nor invention without necessity.” 
Leonardo da Vinci 
   
 
 
III 
Abstract 
Glioblastoma multiforme (GBM), grade IV Astrocytoma, is the most common 
and deadly form of brain cancer. Despite the low incidence rate (3.2 per 100.000 
people), patient’s median survival is only 14 months. Notwithstanding all new 
diagnostic tools, GBM remains a therapeutic challenge, being extremely difficult to 
prevent recurrence. Therefore, it is essential to conduct research in order to 
understand the molecular pathways in the core of GBM aggressiveness and swift 
evolution. 
GBM is often characterized by hypoxic regions where oxygen levels are 
extremely low. As a natural consequence of tumour growth and expansion, some 
areas of the tumour become distanced from the blood vessels and consequently, from 
the oxygen supply. In such a critical environment, cells activate pro-survival and 
malignancy mechanisms such as the metabolic switch, invasion and angiogenesis. 
Hence we investigated the expression of genes featuring these survival mechanisms 
and identified a panel of hypoxia-driven-malignancy markers.  
To conduct this study, two GBM patient´s biopsy-derived cell lines (UP-029 and 
SEBTA-023) were used and cultured under hypoxic conditions for a selected set of 
time-points (time-course). To characterize the hypoxic response of these cells, 
hypoxia profiler microarrays were ran for normoxia, 6 and 48 hours of hypoxia (1% 
O2). Once identified the induced and repressed genes, these were analyzed and 
validated through qRT-PCR assays. Finally, western-blot analysis was performed to 
detect target proteins and correlate with the previously obtained gene expression data.  
Our study validated ANGPTL4, PIGF, VEGFA, GLUT1, PFKB4, PFKB3, BNIP3, 
DDIT4, NDRG1 and CAIX genes as relevant in GBM’s hypoxia-mediated response. 
We also pointed out MXI1, HNF4A genes as likely significant factors in GBM hypoxia. 
Furthermore, we hypothesize PFKB3 as an adaptive resistance marker in GBM and 
the repression of TFRC as required mechanism for GBM progression.  
 
Keywords: Glioblastoma (GBM); Hypoxia; Angiogenesis; Glycolysis; Invasion 
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Resumo 
 
O Glioblastoma multiforme (GBM) é a forma mais comum e letal de cancro no 
sistema nervoso central. Devido às suas caraterísticas altamente invasivas e 
malignas, o Glioblastoma foi considerado pela World Health Organization (WHO) 
como um Astrocitoma grau IV. Contrariamente a outros tipos de cancro de igual grau, 
a capacidade de invasão do GBM é limitada ao tecido cerebral.  
 
Apesar dos avanços nas tecnologias de diagnóstico e dos constantes 
progressos na investigação do cancro, o tratamento do GBM é meramente paliativo. 
A seletividade farmacológica da barreira hemato-encefálica, a elevada 
heterogeneidade tumoral e influência destrutiva do tumor no tecido nervoso, refletem-
se na ineficiência das terapias aplicadas.  
 
Clinicamente, o GBM manifesta-se através de pressão intracranial, cefaleias 
e/ou défices neurológicos tais como, alterações visuais, alterações da fala, 
dificuldades cognitivas e até modificações na personalidade. Embora, menos 
frequentes, convulsões também se encontram descritas como um dos sintomas.  
 
A taxa de incidência deste tipo de carcinoma é de facto baixa, sendo que em 
100000 apenas 3.2 pessoas são afetadas. Não obstante, a média de sobrevida destes 
pacientes é somente 14 meses. Conduzir investigações no sentido de entender os 
mecanismos moleculares que se encontrar subjacentes à expansão e agressividade 
do GBM torna-se, portanto, essencial.  
 
Uma das características mais proeminentes do GBM são as regiões hipóxicas, 
onde os níveis de oxigénio são extremamente baixos. Esta é uma consequência 
natural, derivada da expansão tumoral e do incremento da distância de difusão de 
oxigénio. Estabelecido um microambiente como este, crítico para a sobrevivência 
celular, as células tumorais ativam mecanismos de malignidade tais como “switch” 
metabólico, angiogénese e invasão. Desta forma as células adquirem vantagem 
clonal e capacidade migratória para invadirem zonas de tecido cerebral saudável. 
Para além do incremento da malignidade, a elevada capacidade invasiva destas 
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células constitui um risco em termos de recorrência. De um modo geral, a hipóxia 
integra-se como um marcador de mau prognostico. 
 
Para este estudo, duas linhas celulares obtidas através de biópsias de 
pacientes com GBM (UP-029 e SEBTA-023), foram incubadas a diferentes tempos 
de hipóxia. Após extração de ácido ribonucleico (ARN), realizou-se um microarray de 
perfil de hipóxia a três amostras em diferentes condições: normóxia (controlo), 6 e 48 
horas. O método do microarray baseia-se na tecnologia de reações de polimerase em 
cadeia e em tempo real (RT-PCR). Este, por sua vez, é um método de quantificação 
de expressão génica através da geração de cópias (por ciclo de PCR) a partir de um 
ADN molde. Isto origina uma correlação entre a quantidade inicial de cópias e a 
quantidade acumulada a cada ciclo. Desta maneira, foi possível quantificar a 
expressão génica de 84 genes previamente descritos na literatura como relacionados 
na resposta hipóxica em diversos tipos de cancro. Este ensaio permitiu-nos identificar 
em larga escala diversos marcadores de hipóxia que foram diferencialmente 
expressos com significância. Do painel analisado, destacaram-se os genes 
ANGPTL4, NDRG1, CAIX, PFKB4 e VEGFA como relevantemente induzidos tanto 
nas UP-029 como nas SEBTA-023. Para além destes, os genes MXI1, HNF4A e 
TFRC foram estabelecidos como significativamente sub-expressos durante a hipóxia 
nas duas linhas celulares de GBM.  
 
Continuando com a análise, estudámos através de ensaios de RT-PCR 
quantitativo os vários genes distinguidos acima, tal como outros apenas 
diferencialmente expressos numa das linhas celulares durante a hipóxia. Cada gene 
foi analisado em quatro condições diferentes: normóxia, 6, 24 e 48 horas de hipóxia, 
em pelo menos três corridas diferentes. O método de 2-ΔΔCT foi usado para calcular o 
fold-change de cada gene, que nos transmite a magnitude biológica da expressão de 
um gene relativamente a um controlo. De modo a estudar a significância estatística 
dos resultados, usámos Students T-test  (tipo 2, cauda 2) para calcular os P-values 
de cada amostra. Considerámos três níveis de significância para P-values inferiores 
que 0.05 (*), 0.01 (**) e 0.001 (***).  
 
Desta análise de RT-PCR quantitativo, para além dos genes previamente 
distinguidos, também os genes PIGF, PDK1, PFKB3, BNIP3, DDIT4 e SLC16A3 
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foram detetados como significativamente induzidos nas linhas celulares UP-029 e 
SEBTA-023. Validámos, também, o gene TFRC como significativamente sub-
expresso durante a hipóxia.  
 
De modo a analisar a expressão de proteínas de alguns deste fatores, 
realizaram-se ensaios de Western-blot. Esta é uma técnica vastamente usada em 
laboratório que permite a identificação de proteínas específicas de uma amostra de 
proteína total. Este método consiste na separação de proteínas por pesos 
moleculares através da aplicação de voltagem. Para tal, a amostra proteica é 
desnaturada através de calor e posteriormente pipetada num gel de eletroforese. As 
proteínas (carga negativa) migram através do gel na direção do polo positivo, assim 
que aplicada voltagem. Desta forma, as moléculas menores migram mais 
rapidamente e facilmente para a base do gel que as de maior peso molecular, que 
ficam mais próximas do topo. Após separação e transferência para uma membrana 
de nitrocelulose, é possível sinalizar estas proteínas através de complexos de 
anticorpos e fluoróforos. Assim, pudemos detetar a expressão proteica de alguns 
genes de interesse em diferentes condições: normóxia, 1, 2, 3, 6, 24 e 48 horas de 
hipóxia.  
 
Realizou-se uma análise de expressão proteica de HIF1a para confirmar a 
indução da resposta hipóxica. Uma vez que é regulado a nível da proteína, foram 
detetadas, de facto, bandas de HIF1a durante a hipóxia , apesar de não se 
observarem induções significantes da expressão génica. Como CAIX, foi 
significativamente expresso a nível do gene, foram também realizados blots para a 
proteína correspondente. A proteína CAIX foi detetável nas amostras de 6, 24 e 48 
horas de hipóxia, especialmente nas células SEBTA-023.  
 
A proteína EGFR, vastamente descrita em GBM, foi também analisada.  
Curiosamente não foi detetável nas células UP-029, mas sim nas SEBTA-023, em 
todas as amostras. À semelhança de EGFR, os blots das proteínas UpaR, VEGFC e 
S100A10 foram também analisados. As proteínas UpaR e S100A10 foram detetadas 
em ambas as linhas celulares, com distinção nas amostras SEBTA-023. Nas células 
UP-029 a baixa deteção de proteína pode-se justificar por uma activação mais tardia 
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da expressão de factores de invasão. Curiosamente a expressão de VEGFC, 
detetável em ambas as linhas, diminuí em simultaneidade com o aumento de horas 
de hipóxia.  
   
 Em suma, o nosso estudo identificou ANGPTL4, NDRG1, CAIX, PFKB4, 
VEGFA, PIGF, PDK1, PFKB3, PFKB4, BNIP3, CAIX, DDIT4, NDRG1 e SLC16A3 
como genes significativamente induzidos e HNF4A e TFRC como genes 
significativamente sub-expressos em GBM. Extrapolámos, que por vezes a indução 
das expressões de genes e proteínas de invasão é uma resposta tardia após um 
período considerado crónico de hipóxia. De futuro, deveriam ser estudados tempos 
de hipóxia mais prolongados, como 72 e 96 horas. Sugerimos, também, PFKB3 como 
um provável marcador de resistência à terapia, uma vez que já se encontra descrito 
noutros tumores, e neste estudo foi significativamente induzido. Conjuntamente, 
propõe-se o TFRC como um possível fator importante no impedimento da progressão 
do GBM, uma vez que foi sub-expresso nas diferentes análises. Estudos relativos a 
estes dois genes deverão ser conduzidos no futuro, para confirmar as hipóteses 
acima. Seria também relevante repetir este estudo aumentando o número de linhas 
celulares de modo a elevar a sensibilidade da seleção de possíveis novos marcadores 
de invasão em hipóxia.  
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1. Introduction  
Glioblastoma (GBM) is the most common form of brain cancer, with its origin in 
glial cells or neural stem cells from the central nervous system (CNS) (Lombardi & 
Assem, 2017). Due to its highly invasive and aggressive nature, GBM is classified by 
the WHO (World Health Organization) as a grade IV Astrocytoma (Gupta & Dwivedi, 
2017). Unlike other grade IV malignancies, GBM invasiveness seems to be exclusive 
to the brain microenvironment. Nevertheless, the destructive influence on brain tissue, 
and the heterogeneity of the tumour and its associated microenvironment, constitute 
great obstacles for the efficacy of current therapies (Lombardi M, Assem M, 2017). In 
fact, within all human tumours, GBM is considered one of the most lethal and difficult 
to treat (Paolillo, Boselli, & Schinelli, 2018).  
 
The clinical presentation of GBM may vary depending on the location of the 
tumour. The most common symptoms include increased intracranial pressure, 
headache and focal or progressive neurologic deficits. Nearly 25% of the patients have 
seizures as an early event, while at a later stage close to 50% suffer from this symptom 
(Davis, 2016). 
 
The known risk factors for GBM are ionizing radiation and genetic diseases. 
Patients that undergo therapeutic radiation for another tumour or condition may be 
affected in the future by a radiation-induced GBM. Also, there is an increased risk of 
GBM in patients suffering from genetic diseases such as neurofibromatosis 1 and 2, 
tuberous sclerosis, Li-Fraumeni syndrome, retinoblastoma and Turcot Syndrome. 
Approximately 1% of GBM patients are known to have a hereditary disease. 
Environmental exposures to chemicals such as smoking, pesticides, petroleum 
refining, etc. may also be correlated to GBM (Davis M, 2016). Electromagnetic fields 
and nonionizing radiation from cell phones were not proved to lead to GBM 
development (Davis M, 2016).  
 
GBM incidence is slightly higher in men than women, as well as in Caucasians 
as compared to other ethnicities. The average incidence rate is 3.2 per 100.000 
people. The median survival after surgery and chemotherapy acknowledged by 
population-based studies is only 14 months (Delgado-López & Corrales-García, 2016; 
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Davis M, 2016). Even though more common in advanced ages (median 64 years old), 
GBM may occur at any age. In fact, GBM is the most common pediatric solid tumour. 
The prognosis in children is slightly better than in adults, due to biological 
dissimilarities, however it still remains poor (Das K & Kumar R, 2017; Davis M, 2016). 
Despite all treatment efforts, about 70% of GBM patients experience disease 
progression within one year of diagnosis and less than 5% (adulthood GBM) and 20% 
(pediatric GBM) survive five years after the diagnosis. Indeed, second line treatments 
are basically palliative care in order to optimize life quality (Das & Kumar, 2017; Davis, 
2016). 
 
Despite all new diagnostic tools, GBM remains the most deadly type of 
malignant brain tumour with a very low median survival rate (Monteiro, Hill, Pilkington, 
& Madureira, 2017). Nowadays, the inability to predict sensitivity or resistance to 
therapies as well the challenge of achieving an optimal CNS bioavailability lead to an 
unfortunate scenario for GBM patients (Lombardi M, Assem M, 2017). Studies 
regarding this disease are imperative in order to improve prophylaxis, early diagnosis, 
prognosis and treatment prediction to lead to a better outcome. Moreover, 
understanding the molecular pathways in the core of GBM aggressiveness and swift 
evolution may be half way towards a paradigm change (Lombardi M, Assem M, 2017).   
 
1.1 Glioblastoma classification    
GBM can be assembled into two distinct groups: primary and secondary. Primary 
GBM, most common (approximately 90% of all cases), develop from a glioma 
precursor cell without evidences of precursor lesions. On the other hand, secondary 
GBM is the consequence of a lower-grade glioma (e.g. Grade II astrocytoma) 
progression. While primary GBM is more common in elderly, secondary GBM 
manifests preferentially in younger patients. Although histologically similar, primary 
and secondary GBMs are differentiated by distinct genetic and epigenetic landscapes 
(Ohgaki & Kleihues, 2013).  
 
1.1.1 Primary Glioblastoma 
Primary GBMs are typically characterized by PTEN mutations, loss of chromosome 
10 and overexpression of the Epithelial Growth Factor receptor (EGFR) (Ohgaki & 
Kleihues, 2013). Although the loss of heterozygosity (LOH) of chromosome 10q may 
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be found on both GBM types and linked to loss of PTEN in the secondary tumours, 
spontaneous mutations of PTEN are exclusive of primary GBM (Mansouri, 
Karamchandani, & Das, 2017). The LOH of chromosome 10 represents by itself a poor 
molecular prognosis marker. Indeed, this loss can, in some cases, be linked with the 
PTEN inactivation, since this tumour suppressor gene cytogenetic location is 10q23.3, 
as illustrated on Figure 1.1 (Balesaria et al., 1999). 
 
 
 
 
 
 
PTEN (Phosphatase and tensin homolog) mutation is believed to be an early 
event of glioma carcinogenesis (Feng et al., 2016). When lacking this protein, 
PI3K/AKT/mTOR pathway becomes constitutively activated, leading to an immortal 
path of uncontrolled growth and survival. PTEN, as the major regulator of this pathway 
(shown in Figure 1.2), is a key tumour suppressor and as such its inhibition fuels the 
carcinogenesis process (Chalhoub & Baker, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
PTEN gene 
q23.3 
Figure 1.1. PTEN gene cytogenetic location on Chromosome 10. Schematic representation of 
chromosome 10, highlighting the location of the PTEN gene in red. Adapted from 
https://ghr.nlm.nih.gov/gene/PTEN/location.png 
 
RHEB 
PTEN 
PI3-kinase 
PIP 2 P P PIP 3 P P P 
PDK1 AKT 
 TCS1 
TCS2 
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Cell Survival 
Cell metabolism 
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Inhibitory pathway 
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Inactivated pathway 
Oncogenic 
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Tumour Suppressor 
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Figure 1.2. PI3K oncogenic pathway, when PTEN is inactivated. When PTEN protein is 
inactivated PIP3 remains active. This will lead to and over-activation of the mTOR that signals for cell 
survival, metabolism, proliferation and growth. 
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Along with PTEN loss, the EGFR over-activation is intimately related with cell 
survival, proliferation and invasion pathways, which constitute imperative hallmarks 
for cancer progression. Indeed, this protein is overexpressed in ~60% of primary 
GBMs, featuring a more aggressive phenotype (HONGSHENG et al., 2017). This 
membrane receptor signals to some of the most important oncogenic pathways, the 
MAPK/ERK and the PI3K/AKT/mTOR pathways, both illustrated on Figure 1.3.  
 
Nearly 88% of gliomas develop alterations in the MAPK/ERK pathway, which 
is translated in a poor survival prognosis. Moreover, this signaling pathway is also 
known to lead to increased therapy resistance (Pandey, Bhaskara, & Babu, 2016). 
Additionally, the over-activation of the PI3K/AKT/mTOR pathway is also a poor 
prognostic marker (X. Li et al., 2016). Not only the lack of PTEN contributes for the 
abnormal PI3K activity, constitutively active EGFR also induces this pathway. In fact, 
both EGFR and PTEN mutational events seem to be harbored in a significant number 
of GBMs as mutually inclusive genetic events (Arif et al., 2015). 
 
1.1.2 Secondary Glioblastoma 
Secondary GBM mutational landscapes frequently show TP53 and ATRX loss, 
chromosomes 1p and 19q co-deletion and Isocitrate dehydrogenase 1 (IDH1) 
mutations. Indeed, IDH1 mutation is a well-established molecular marker of all 
secondary GBMs, while TP53, ATRX mutations and co-deletion of both chromosomes 
Figure 1.3. EGFR induced signaling pathways. EGFR induces two oncogenic pathways, when 
mutated, which leads to overactivation of the RAS-RAF-MEK-ERK and AKT-mTOR signaling chains. 
Inhibitory pathway 
Inductor pathway 
Inactivated pathway 
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1p and 19q depend on the type of precursor tumour. TP53 and ATRX loss are 
mutational marks of an astrocytoma precursor. On the other hand, loss of 
chromosomes 1p and 19q are typical of oligodendrogliomas (Mansouri, 
Karamchandani, & Das, 2017). More than a molecular marker, IDH1 mutations are of 
great clinical significance since they represent a better prognosis (Cohen A, Holmen 
S & Colman H, 2013).  
 
Mutations targeting IDH1 result in the loss of this enzyme normal activity. While in 
the healthy system, this protein has the catalytic function of producing a-Ketoglutarate 
(a-KG) and NADPH, in a tumour environment, mutated IDH1 produces 2-
hydroxyglutarate (2-HG) and NADP+, as exhibited in figure 1.4.  
 
 
 
 
 
 
 
 
 
NADPH is a very important metabolite for proliferation, since it is involved in cellular 
processes such as defense against oxidative stress, glycolysis and synthesis of fatty 
acids. However, IDH1 mutations result in a decrease of NADPH cellular levels as this 
molecule acts as an electron donor to produce 2-HG. It is not yet clear if the reduced 
levels of this metabolite is the reason why secondary GBMs have a slower tumour 
growth rate (Yang, Ye, Guan, & Xiong, 2012). Since NADPH is a critical metabolite for 
the cellular detoxifying process against Reactive Oxygen Species (ROS), this could 
also be a possible cause for mutated IDH1 better prognosis (van Lith et al., 2014). 
 
Similarly, α-KG plays an important role in GBM tumour cell metabolism. As the only 
structural difference between α-KG and 2-HG molecules is the replacement of the 2-
ketone group for a hydroxyl group. This leads to 2-HG acting as a competitive 
antagonist. This results in the inhibition of many a-KG-dependent dioxygenases, such 
as lysine histone demethylases (KDMs) and Ten-Eleven Translocation (TET) family of 
Mutant: 
2-HG 
NADP+ NADPH 
Isocitrate 
Wild-Type: 
a-KG 
NADP+ NADPH 
IDH1 IDH1 
Figure 1.4. Comparison of IDH1 Wild-type (wt) with IDH1 Mutant. The catalytic reaction lead by wt 
IDH1 has as products NADPH and a-KG. When mutated, NADP+ and 2-HG are the catalytic products. 
a-KG 
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DNA hydroxylases. In this way high 2-HG concentrations in GBM cells lead to a global 
DNA hypermethylation phenotype, illustrated in Figure 1.5, altering gene expression 
and inhibiting differentiation (Maus & Godefridus, 2017).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Although not yet clear how IDH1 mutations are translated into better outcomes, 
the hypermethylated phenotype resultant from IDH1 mutations may be a main reason 
by affecting the expression of DNA repair proteins (such as MGMTs), leaving cells 
vulnerable to DNA alkylating therapeutics. Additionally, the fact that mutated IDH1 
lacks the ability to reverse 2-HG or a-KG into Isocitrate, as illustrated in Figure 1.4, 
may also be related with a better outcome. Isocitrate is a substrate to generate citrate 
for lipid synthesis, central in cell proliferation and maintenance. Therefore, low levels 
of citrate may have a great impact on cell survival (van Lith et al., 2014).  
 
Even though IDH1 is a central molecular marker for the identification of secondary 
GBMs, there are more mutational hints in these tumour landscapes. Not only these 
hints may characterize a tumour as a secondary GBM, it might even represent 
evidences of a specific precursor tumour.  
 
Astrocytomas are brain tumours with origin in the star-shaped brain glial cells 
called astrocytes (Killela et al., 2013). As mentioned before, TP53 and ATRX losses 
Figure 1.5. Mutated IDH1 generates 2-HG which by inhibiting TET and KDMs leads to genome 
hypermethylation. This will result in altered gene expression and inhibition of differentiation. 
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are both common in astrocytomas. Indeed, the loss of TP53 is one of the most frequent 
and earliest mutations in the developing astrocytoma. This early event results of a 
mutation G:C®A:T on the CpG sites that mostly occur in the hotspot codons 248 and 
273 (Ohgaki & Kleihues, 2007). In its wild-type form, TP53 is a transcription factor 
activated when DNA damage is detected in the cell cycle. Subsequently, this protein 
is involved in processes such as the regulation of cell cycle arrest and apoptosis, 
illustrated in Figures 1.6a and 1.6b (Sionov & Haupt, 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. TP53 Wild-Type tumour suppressor pathway for:  a. cell cycle arrest TP53 arrests the 
cell cycle in the G1 phase by inducing the expression of P21. When inhibiting CDKs via P21, pRB 
maintains itself in a hypophosphorylated state, sequestering E2F transcription factor. E2F is repressed, 
as well the transcription of its target genes required for the transition to S phase. Additionally, pRB 
recruits HDAC1 which promotes the compaction of the nucleosomes to prevent transcription. P21 is 
a. 
b. 
Inhibitory pathway 
Inductor pathway 
Inactivated pathway 
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also able to halt cellular growth by preventing PCNA (Proliferating Cell Nuclear Antigen) from activating 
DNA polymerase d, central in DNA replication (Sionov & Haupt, 1999);  b. cell apoptosis TP53 also 
induce apoptosis if the DNA damage is too extensive or irreversible. Bax releases cytochrome c from 
the mitochondria, subsequently activating caspase-9 (Haupt S., Berger M., Goldberg Z., & Haupt Y., 
2003). PUMA encodes for two proteins: PUMA-a and PUMA-b that bind to Bcl-2 to release cytochrome 
c and induce cell death in a c/Apaf-1-dependent way (Nakano & Vousden, 2001). When released by 
Bax and PUMA proteins, cytochrome c binds to the Apoptotic Protease Activating Factor 1 (Apaf-1) 
forming the Apoptosome. This complex triggers Pro-Caspase 9, turning it into Caspase 9 (activated 
form), which will in its turn trigger Pro-Caspase 3 (into Caspase 3), finally leading to apoptosis (Ooi & 
Ma, 2013). Lastly, Noxa has been indicated as functioning through an analogous pathway to Bax 
(Shibue et al., 2003). 
 
ATRX (alpha-thalassemia/mental retardation X-linked syndrome protein), member 
of the SN2 family of chromatin-remodeling proteins, has a key role in gene expression 
regulation. This protein exists in two isoforms which take part in the maintenance of 
the stability of the genome and chromatin structure at telomeres (Hoelper, Huang, 
Jain, Patel, & Lewis, 2017; Jones et al., 2017). Although ATRX role in gliomas is not 
yet fully understood, low expression levels of this protein have been linked with 
tumours which overexpress genes involved in signal transduction (GTP-related) as 
well as in transport, modification, and ubiquitination of proteins (Jones et al., 2017). 
Moreover, tumours with this mutation exhibit lengthening of the telomeres (Hoelper et 
al., 2017).  
 
It has been shown that ATRX and TP53 loss, alongside with IDH1 mutations are 
the 3 oncogenic hits required to arrest astrocytoma stem cells differentiation. This 
event promotes gliomaneogenesis by maintaining these cells in a perpetual self-
renewing and invasive state. SOX2 was identified as downregulated in tumours 
harboring these 3-hits. SOX2 expression depends on the CTCF-dependent chromatin 
loop to be able to reach its enhancer 700 kb downstream. However, the 3 P53-ATRX-
IDH1 hits induce the hypermethylation of the CTCF motifs which flank the SOX2 locus, 
meaning that the loop is disrupted, clarified in Figure 1.7 (Modrek et al., 2017). 
 
 
 
 
 
 
 
 
   
 
 
10 
 
 
 
 
 
 
 
 
 
 
 
Although SOX2 is mainly known for its role in promoting pluripotency, in the 
brain it may promote the transcription of pro-neurogenic factors such as Neurod1, 
Ngn1 and Ngn2 (Amador-Arjona et al., 2015). Downregulation of SOX2 was shown to 
be concurrent with downregulation of these pro-neurogenic genes, which may explain 
the differentiation blockage (Modrek et al., 2017). 
 
Secondary GBMs may also evolve from an oligodendrioma precursor. This rare 
type of glioma (<4%) has origin in the oligodendrocyte cells which give support and 
insulation to the axons in the CNS. Classically, oligodendrogliomas feature loss of 
heterozygosity for chromosome arms 1p and 19q as a result from an aberrant 
translocation t (1:19) (q10:p10). This molecular marker, besides its origin identification 
purpose, is of a high clinical significance since it seems to be associated with 
sensitivity to chemotherapy and improved outcome (Wesseling, Van Den Bent, & 
Perry, 2015). Simultaneous loss of 1p and 19q alleles is indeed one of the earliest 
events in the majority of oligodendrogliomas. Such fact suggests that this genetic 
modification confers a selective growth advantage to oligodendroglioma cells. 
However, it is yet unknown which underlying molecular mechanisms are implicated in 
tumour progression (Reifenberger & Louis, 2003). 
 
1.1.3 Molecular Classification of Glioblastoma Subtypes 
Regardless of their primary or secondary origin, GBMs can be categorized into 4 
molecular subtypes: classical, mesenchymal, proneural and neural. This molecular 
classification of GBMs is based in mutational patterns that bear a resemblance with 
CTCF MMe 
MMe 
SOX2 
Enhancer 
CTCF motif 
methylated 
P53 loss 
ATRX loss 
IDH1 mutation 
Differentiation Differentiation 
block 
SOX2 
Enhancer 
CTCF 
Figure 1.7. The role of the 3-hits theory, which will lead to the maintenance of the pluripotency 
phenotype by inactivation of CTCF induced chromatin loop and SOX2 enhancer. 
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the expression profiles of their putative cells of origin (Verhaak et al., 2010). 
Mesenchymal tumours are enriched with both mesenchymal and astroglial signatures. 
While, proneural tumours have a clear sign of an oligodendrocyte development 
(Alcantara Llaguno & Parada, 2016). The neural subtype has an alignment of genes 
which functions are related with the nervous system function and development. On 
the other hand, similarly to the mesenchymal subtype, classical tumours have stem 
cell markers (Lombardi & Assem, 2017). Each subtype is associated to a singular 
molecular signature, indicative of the cell of origin. Yet, the clinical and scientific 
significance of this categorization relies not in the cell of origin but in the mutational 
markers of each tumour type that may or not confer a better prognosis and an 
enhanced therapeutic response. Distinctive mutated molecular pathways may 
establish advantages or disadvantages in terms of therapy response (Verhaak et al., 
2010). 
  
1.1.3.1 Classical 
The classical subtype commonly characterized by the amplification of 
chromosome 7 paired with loss of chromosome 10, features the amplification of EGFR 
and loss of PTEN and CDKN2A (Lombardi & Assem, 2017; Verhaak et al., 2010). 
 
 1.1.3.2 Mesenchymal 
Mesenchymal tumours similarly to the classical subtype, harbor the amplification 
of chromosome 7 and loss of chromosome 10, amplification of EGFR and loss of 
PTEN. However, this subtype has the particularity of NF1 mutations and 
overexpression of the tumour necrosis factor pathway genes TRADD, RELB and 
TNFRSF1A (a potential consequence of the high overall necrosis associated with this 
class) (Lombardi & Assem, 2017; Verhaak et al., 2010). 
 
 1.1.3.3. Proneural 
In the proneural subtype, both PDGFRA and IDH1 mutations are major 
features. Although amplification of PDGFRA is frequently seen in all GBM classes, the 
rates of amplification are much higher in proneural tumours.  Curiously, in these 
tumours it seems that IDH1 and PDGFRA mutations are mutually exclusive events, 
rarely occurring at the same time. Besides these, TP53 mutations are also common 
in this GBM sub-type (Verhaak et al., 2010). 
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1.1.3.4 Neural 
In neural tumours, the expression of neuronal markers such as NEFL, GABRA1, 
SYT1 and SLC12A5 is extremely common (Dunn et al., 2012; Verhaak et al., 2010). 
 
 
 
 
This molecular categorization of GBMs fits into the generic primary and 
secondary classes with different incidence rates, as shown in Figure 1.8. Indeed, 
primary GBMs may be associated with any of the four subtypes. However, secondary 
GBMs are exclusively proneural tumours, being this the only class comprehending 
IDH1 mutations (Morokoff, Ng, Gogos, & Kaye, 2015).  
 
 
 
 
 
 
 
 
 
 CLASSICAL MESENCHYMAL PRONEURAL NEURAL 
Prognosis Poor Poor Good Good 
Cell Origin Stem cells 
Stem 
cells/Astroglial 
Oligodendroglial Neural 
Chromosomal 
Aberration 
Chromosome 7 
 Chromosome 
10 
Chromosome 7 
 Chromosome 10 
No chromosomal 
aberrations 
No 
chromosomal 
aberrations 
Altered 
pathways 
EGFR 
Loss of PTEN 
and CDKN2 
 
EGFR 
NF-Kb pathway proteins 
Loss of PTEN 
NF1 
PDGFA or  
mutation of IDH1 
Loss of PT53 
NEFL, 
GABRA1, SYT1 
and SLC12A5 
 
Table 1.1. The 4 molecular classifications of Glioblastomas and their respective prognosis, cell of origin, 
chromosomal aberration and altered pathways (Verhaak et al., 2010; Lombardi & Assem, 2017).   
  = amplification;    = Downregulation  
Figure 1.8. The 4 molecular classifications of GBMs, sorted into the primary and secondary categories 
and their respective incidence by Verhaak et al. (adapted from Morokoff, Ng, Gogos, & Kaye, 2015).  
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Recently, a new cluster of tumours has been documented: G-CIMP+. This 
molecular subgroup identification is based on the CpG island methylator phenotype 
existent in several GBMs within the four categories previously mentioned, yet 
predominant in tumours which harbor IDH1 mutations (proneural secondary GBMs) 
(Malta et al., 2017; Mansouri et al., 2017). 
 
Generally, these tumours tend to relate with a better outcome and improved overall 
survival translated from the effectiveness of chemotherapy. In G-CIMP+ tumours, the 
MGMT promoter methylation has been established as a favorable prognostic 
molecular biomarker. Moreover, patients with triple combined G-CIMP+ tumours, 
which harbor the co-deletion of 1p/19q chromosomes, IDH mutations and MGMT 
methylation, have a significantly improved overall survival than those who only carry 
the MGMT methylation biomarker (Malta et al., 2017). 
 
1.2 Therapeutic strategies  
Despite all progresses in broad-spectrum cancer therapies development and 
diagnostic technologies, GBM shows one of the worst prognosis, with a high mortality 
rate. Currently, maximal surgical resection followed by concomitant radiotherapy and 
temozolomide chemotherapy is the standard treatment for newly diagnosed tumours. 
Still, there is no standard of care for recurrent or progressive GBM, despite the 
numerous clinical trials. Due to the disease heterogeneity (multiple molecular and 
histological subtypes) and small control groups (low incidence), it is difficult to identify 
the effectiveness of therapies in trials. Alternative therapies, in these cases, vary within 
reoperation, re-irradiation, systemic therapies (new chemotherapies, i.e. 
Bevacizumab) or combined modality therapies (surgery/radiotherapy/chemotherapy) 
(Fernandes et al., 2017). 
 
1.2.1 Surgery  
Surgery is the first therapeutic approach for GBM treatment, aiming to resect 
maximal tumour mass as possible within safety parameters in order to extract tissue 
for pathological diagnosis and delay tumour progression. The more extensive the 
resection is, the longer is the life expectancy. However, the main barrier this method 
faces is the fine balance between the tumour tissue removal and the preservation of 
brain functions and healthy tissue. As a matter of fact, surgeries to tumours located 
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within the eloquent cortex have high risk of postoperative neurological deficits 
(Fernandes et al., 2017). 
 
Prior to surgery, the candidates are determined as good surgical candidates 
through the Karnofsky Performance Scale (KPS), shown in table 1.2. Normally, only 
patients with a KPS index equal or greater to 70 are considered for a surgical 
intervention. Nonetheless, selected patients with lower indexes may sometimes 
benefit from surgery, exhibiting improved survival and quality of life after tumour 
reduction (Young, Jamshidi, Davis, & Sherman, 2015). Marina et al. revealed that 
patients with preoperative KPS lower than 50, indeed improved their KPS status after 
surgery increasing their survival time and functional grade (Marina et al., 2011; Young 
et al., 2015). It is essential to understand that the surgical approach may differ between 
individuals, taking in consideration the localization of the tumour, pre- and 
postoperative KPS, survival extension and life quality (Young et al., 2015). 
 
GENERAL RANKING FUNCTIONAL CRITERIA (%) 
 
Able to carry on normal activity and to work; 
no special care needed 
 
100%: No Complains; No evidence of 
disease; 
90%: Able to carry on normal activities; 
minor signs or symptoms of disease; 
80%: Normal activity with effort; Some signs 
or symptoms of disease; 
 
Unable to work; able to live at home and 
care for most personal needs; varying 
amount of assistance needed 
 
70%: Cares for self; Unable to carry on 
normal activity or to do active work; 
60%: Requires occasional assistance but is 
able to care for most personal needs; 
50%: Requires considerable assistance and 
frequent medical care; 
 
Unable to care for self; requires equivalent 
of institutional or hospital care; disease may 
be progressing rapidly 
40%: Disabled; Requires special care and 
assistance; 
30%: Severely disable; hospital admission is 
indicated although death not imminent; 
Table 1.2. Karnofsky performance status adapted from Young et al., 2015 
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1.2.2 Radiotherapy 
After surgery and previously to radiotherapy, patients are administered with 
dexamethasone, a corticosteroid, in order to prevent brain swelling. This is particularly 
important in patients whose tumour exerts were significant. Also, it may prevent 
radiotherapy associated brain swelling that can worsen the patient’s symptoms 
(Kostaras, Cusano, Kline, Roa, & Easaw, 2014). 
 
Currently, the standard radiotherapy is given in concomitance with chemotherapy 
and may vary between 5.000-6.000 cGy doses fractionated over 30 days, in order to 
allow healthy cells of the irradiated zone to recover. Postoperative radiotherapy in 
these doses has been validated as beneficial in terms of survival advantage. However, 
dose-escalation beyond these values resulted in increased toxicity without being 
beneficial in terms of survival  (Barani & Larson, 2015).  
 
Notwithstanding the standards and what is considered the ideal dose, how 
radiotherapy is applied may depend on the age of the patient, tumour size and 
location. Normally, patients up to 70 years old, with a reasonable KPS status receive 
standard treatment of 6.000 cGy in fractions of 2 Gy. Whereas 70 years old patients 
should receive a less aggressive treatment of 4.000 cGy in fractions of 2,66 Gy 
(Cabrera et al., 2016). As a localized treatment, it is crucial to perform imaging 
diagnostics of the tumour prior to therapy. This helps define the target volume and 
localization. There are four important notions that help with the radiotherapy planning 
concerning the volume and localization, as well as the effectiveness and safety: Gross 
Tumour Volume (GTV); Clinical Target Volume (CTV); Planning Target Volume (PTV) 
and Organs at Risk (ORs). The first, GTV refers to the volume to be irradiated which 
can be seen and imaged (primary tumour). Secondly, the CTV means to target the 
spreading cells surrounding the primary tumour, which cannot be fully imaged. 
 20%: Very Sick; Hospital admission 
necessary; Active supportive treatment 
necessary; 
10%: Moribund; Fatal processes progressing 
rapidly; 
0%: Dead. 
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Following, the PTV contains the CTV irradiated volume with slightly wider margins to 
account for possible variations in the beam alignment, patient position, organ motion 
and deformation. Finally, it is important to consider the volumes to be irradiated, in 
order to protect the ORs from being targeted with a higher-than-safe dose (Burnet, 
Thomas, Burton, & Jefferies, 2004). 
 
The side effects of radiotherapy usually start in the first week after initiating 
treatment and include hair loss, nausea and fatigue (“Side effects of radiotherapy | 
Brain tumour (primary),” 2015). Although rare, patients may also experience side 
effects that start months or years after treatment, once the brain tissue damage can 
reduce the blood supply to certain areas of the brain. This effects may vary between 
impaired memory, confusion and personality changes (“Long term side effects of 
radiotherapy | Brain tumour (primary),” 2015). 
 
1.2.3 Chemotherapy 
Following surgery adjuvant chemotherapy is given in concomitance with 
radiotherapy. Despite all lines of treatments GBM prognosis remains one of the 
poorest within all cancer types. Dysregulation of signaling pathways is widely studied 
nowadays and therapeutic approaches have been made to target proteins within these 
pathways. Several oncogenic pathways inhibitors have been tested in pre-clinical and 
clinical trials for this type of cancer. It is assumed that in the future, combinations of 
these drugs with cytotoxic chemotherapeutic (p.e. Temozolomide) and radiation could 
improve the prospective survival of GBM patients. However, cytotoxic chemotherapy 
remains for the moment the standard treatment as the most advantageous in terms of 
survival, within all approved drugs (Minniti, Muni, Lanzetta, & Enrici, 2009). 
 
1.2.3.1 Temozolomide 
Temozolomide is a cytotoxic alkylating agent reportedly discovered by a mix of 
“intelligence, guesswork, dogged persistence and luck” in 1970 (Newlands, Stevenst, 
Wedge, Wheelhouse, & Brock, 1997). This orally administrated drug is non-
enzymatically hydrolyzed into 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide 
(MTIC) at physiological pH, its active form. MTIC, once activated, alkylates DNA at N7 
position of guanine (most common), O3 position of adenosine and O6 position of 
guanosine (most critical). The methylation of these residues leads to DNA strand 
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breaks and subsequent cell apoptosis (Temozolomide, DrugBank Database, 2005). 
The cytotoxic effect of this drug is correlated with the intracellular levels of MGMT. As 
a critical DNA repair protein, MGMT has the ability to reverse temozolomide’s strand-
breaking action. High levels of MGMT are associated with temozolomide resistance. 
On the other hand, MGMT epigenetic silencing (methylation) is correlated with 
enhanced temozolomide sensitivity, which predicts a good outcome as benefit from 
this therapy. It has been reported that the 2-year survival rates for patients treated with 
radiotherapy and temozolomide with no MGMT methylation was 14%, whereas in 
patients with MGMT silencing, it was  46%. Nevertheless, it has been demonstrated 
through clinical trials that temozolomide increases significantly survival rates with 
minimal additional toxicity, when added to radiotherapy. Indeed, the reported 2-year 
survival rate for radiotherapy and temozolomide in concomitance was 27%, while 
radiotherapy by itself was only 10% (Minniti et al., 2009). 
 
1.2.3.2 Carmustine 
Carmustine is an alkylating agent which cross-links in the DNA and RNA to 
inhibit its synthesis and translation, respectively (Carmustine, DrugBank Database, 
2005). In addition, Carmustine causes oxidative stress by inhibiting glutathione 
reductase, leading to activation of caspase-3 and apoptosis (Castaldo, Freitas, 
Conchinha, & Madureira, 2016). Systemic administration of this drug has 
demonstrated low efficacy in GBM treatment. However, a different method was 
developed: Carmustine wafers (Gliadel® wafers). This new method consists in a 
controlled release of carmustine from biodegradable polymer wafers that are placed 
in the cavity left by the surgical removal of the brain tumour. This approach not only 
reduced systemic toxicity, but it also increased the effectiveness of the therapy (Lin & 
Kleinberg, 2008). Carmustine wafers are approved to treat newly-diagnosed and 
recurrent GBM as an adjuvant treatment, alone or in combination with temozolomide, 
when surgical removal of the tumour is possible. Trials have not yet been conducted 
in order to compare carmustine wafers treatment to temozolomide, as single 
therapies. Despite the therapeutic benefits of this approach, risks associated with this 
treatment should not be disregarded. Cerebral edema, healing abnormalities, 
intracranial infections, seizures, intracranial hypertension and cerebrospinal fluid leaks 
are among the side effects that may be experienced by the patients who undergo this 
treatment and should be taken into consideration when prescribing it (Chowdhary, 
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Ryken, & Newton, 2015). Plus, combination of carmustine wafers with the standard 
treatment may carry the risk of increased secondary events and might not significantly 
improve the outcome (De Bonis et al., 2012).  
 
1.2.3.3 Targeted therapies 
As mentioned above, GBM is characterized by aberrant activation of signaling 
pathways that lead to tumour progression. Inhibitors for growth factor receptors and 
pathways such as MAPK/ERK and PI3K/mTOR or cell cycle control were developed 
and could be adapted as GBM adjuvant therapies, as shown on Table 1.3 (Touat, 
Idbaih, Sanson, Ligon, & Ligon, 2017). 
 
 
 
In addition to these target pathways, in 2009 the Food and Drug Administration 
(FDA) approved provisionally an anti-angiogenic target drug called Bevacizumab for 
recurrent GBM treatment (Touat et al., 2017). Angiogenesis, the process of blood 
vessels growth from the existing vasculature, is a major hallmark of carcinogenesis 
and a very important feature in GBM invasion. Vascular Endothelial Growth Factor 
(VEGF) promotes proliferation and migration of vascular endothelial cells, as well as 
vascular permeability. It is consequently the main player of the angiogenic process. 
Bevacizumab is a monoclonal antibody that targets VEGF-A to inhibit its assembly 
with the respective receptor and so inhibits tumour vascularization (Keating, 2014). 
GENE ALTERATION CANDIDATE THERAPY 
Growth Factor Receptors: 
EGFR Amplification Rindopepimut (EGFRvIIi-specific peptide conjugated) 
 
PDGFR Amplification Dasatinib (PDGFR inhibitor) 
MAPK and PI3K/mTOR pathways: 
PTEN Delection Voxtalisib (mTOR/PI3K inhibitor) 
PIK3CA Amplification Buparlisib (PI3K inhibitor) 
BRAF Mutation 
(phosphomimic) 
Trametinib (MEK inhibitor) or Vemurafenib (BRAF 
inhibitor) 
Cell Cycle pathways: 
MDM2 Amplification AMG232 (MDM2 inhibitor) 
CDK4/6 Amplification Ribociclib (CDK4/6 inhibitor) 
Others: 
IDH1 Mutation AG120 (IDH1 inhibitors) 
Table 1.3. Genomic alterations and example of targeted therapies, adapted from Touat et al., 2017    
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Although it failed to prolong overall survival in newly diagnosed GBM and first 
recurrence, it is frequently used as a last-line treatment following temozolomide, 
carmustine and radiotherapy failure (K. J. Wenger et al., 2017). 
 
1.2.3.4 Therapy resistance 
GBM remains a therapeutic challenge being extremely difficult to prevent 
recurrence. Tumour regrowth typically occurs around the surgical cavity due to the 
failure of standard and targeted therapies, which do not comprise tumour 
heterogeneity. GBM cell subgroups are characterized by divergent expression profiles 
and genetic/epigenetic landscapes, derivative of differences in cell of origin and 
accumulation of mutations (Osuka & Meir, 2017). The clonal evolution theory states 
that cancers develop through a process of clonal expansion and selection in which 
tumours adapt to the surrounding environment. This leads to genetic diversification 
within the tumour architecture as shown in Figure 1.9 (Greaves & Maley, 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Multiple study findings have shown that the higher the tumour heterogeneity 
levels, the lower the response of the patients to anticancer therapies (Dagogo-Jack & 
Shaw, 2017). Some of the tumour cell clones may evade from therapies due to their 
own ‘resistant’ genomic landscape. Indeed, drugs and radiation may artificially select 
resistant cell variants with increased malignant potential (Greaves & Maley, 2012). It 
has been further hypothesized that selection of resistant clones might occur through 
Environment selective 
pressure 
Oncogenic hit 
Original cell 
Normal cell 
M
ut
at
io
n 
ac
cu
m
ul
at
io
n 
Tumour 
Figure 1.9. Clonal evolution theory: The clonal expansion leads to cell populations with different 
mutational landscapes (different colors) and different levels of mutational accumulation. Also, the tumour 
environment and external factors (therapy) contribute for the intratumoral heterogeneity. 
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surgery resection. Non-resected GBM cell populations with stem-like properties that 
through innate and adaptive resistance survive to treatments, repopulate the primary 
tumour site. These resistant cells will then initiate recurrence turning into recurrence-
initiating stem-like cancer (RISC) cells (Osuka & Meir, 2017).  
 
Besides external factors, some environmental features may also interfere with 
selection, introducing the surrounding cells with selection forces that lead to clonal 
assortment (Osuka & Meir, 2017). GBM is characterized by quite diverse histological 
hallmarks. These tumours are organized in specific niches with different features and 
functions within the tumour microenvironment. Three specific tumour niches have 
been identified as the most prominent for GBM regulation: The perivascular, vascular-
invasive and hypoxic niches (Hambardzumyan & Bergers, 2015). The first refers to 
the tumours stem cell nest, where both tumour growth and differentiation are assured. 
In the vascular-invasive region, cells endorse tumour spreading into the brain 
parenchyma by promoting angiogenesis (Hambardzumyan & Bergers, 2015). Finally, 
the hypoxic niche, surrounds the necrotic core and its main feature is the low levels of 
oxygenation which derive from the absence of vasculature. This last precinct might be 
the most influential environment in terms of invasion and tumour spreading. 
Consequently, these cells activate mechanisms to evade from the hypoxic site and 
invade into brain’s healthy tissue (Monteiro et al., 2017). In fact, these cells acquire 
such an invasive  and migratory phenotype that the hypoxic field surroundings is 
characterized by palisading tumour cells, a well-known morphological hallmark of 
GBM (Hambardzumyan & Bergers, 2015). This feature constitutes a poor prognosis 
predictor and challenge in terms of therapy, however hypoxia may defy treatments 
through other individualities. Several studies have shown that hypoxia promotes 
stemness by increasing expression of cancer stem cell markers such as CD133, Sox2, 
Oct4, nestin and Klf4 (Hambardzumyan & Bergers, 2015). This may lead to recurrence 
through RISC cells as already reviewed (Osuka & Meir, 2017). Furthermore, it is also 
known that hypoxia constitutes a barrier to radiotherapy efficacy. Oxygen improves 
cancer cells sensitivity to irradiation and so, the effectiveness of radiotherapy. In 
oxygen privation, cells may survive to therapy to initiate recurrence later (Brown, 
1999).  
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1.3 Hypoxia in Glioblastoma  
As mentioned above, some tumour cells are exposed to hypoxic conditions, 
meaning that the cells demand of oxygen exceeds the supply. This is a natural 
consequence of tumour growth and expansion which leaves cells near the core distant 
from the oxygen supplier blood vessels. In such a critical environment, hypoxic cells 
activate pro-survival mechanisms such as metabolic changes, invasion pathways and 
tumour vascularization signaling. In order to do so, there is a family of transcription 
factors that play the most fundamental role in this hypoxic response: the Hypoxia 
inducible factors (HIFs). (Monteiro et al., 2017) 
 
1.3.1 Hypoxia Inducible Factors 
HIF transcription factors are, without a doubt, the master regulators of the 
hypoxia response. These transcription factors are heterodimeric complexes 
constituted by O2 regulated a subunits (HIF1a, HIF2a and HIF3a) and the 
constitutively expressed b subunit (HIF1b). Within the complex, the a subunits are the 
determinant elements for these transcription factors action.  HIF1a and HIF2a are 
considered the main regulators of the hypoxic response (Monteiro et al., 2017). 
 
When the oxygen levels are normal, prolyl hydroxylases 1-3 (PHD1-3) 
hydroxylate two prolyl residues within the HIFα subunits allowing the binding of the 
von Hippel-Lindau (VHL) protein. This way, VHL protein recruits E3 ubiquitin ligases 
to target HIFα for proteasomal degradation, illustrated in Figure 1.10. However, in a 
hypoxic environment PHDs are inhibited which leads to the stabilization of the HIFα 
subunits. HIFα translocate into the nucleus to bind with HIF1β, forming the 
transcription factor complex which subsequently binds to co-activators and promoters 
of target genes orchestrating the response to hypoxia, Figure 1.10. Although both 
activated by a hypoxic setting, HIF1a and HIF2a are differentially expressed. While 
HIF1a is ubiquitously expressed, HIF2a is selectively expressed in distinct cell 
populations and both play different roles in tumorigenesis, having overlapping as well 
as distinct target genes (Monteiro et al., 2017). 
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When hypoxia-triggered, HIF will induce the transcription of hundreds of genes 
that promote survival mechanisms, angiogenesis, metabolic reprogramming 
(glycolysis), invasion and metastasis. Hence, identifying and characterizing hypoxia 
upregulated pathways in GBM is crucial for the development of novel and more 
effective therapies against this deadly type of tumour (Monteiro et al., 2017). 
 
1.3.2 Angiogenesis 
Angiogenesis is the physiological feature in which new blood vessels are 
developed from pre-existing vessels. Angiogenesis is a well-organized and common 
event in adults (in the menstrual cycle and tissue repair/remodeling), as well in the 
embryonic and fetal development (Kaur, Tan, Brat, & Van meir, 2004). However, it is 
also a very important process for tumour survival and invasion since blood vessels are 
the cells suppliers of oxygen and nutrients (Keating, 2014). GBM is known to be 
among the most vascularized tumours and frequently depicted by microvascular 
hyperplasia (micro-aggregates of endothelial cells). In fact, the hyperbolic form of 
micro-aggregates, called glomeruloid body, is frequently reported in GBM (Kaur et al., 
2004). It is not yet clear if this is a result of a dysfunctional cell proliferation or an 
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Figure 1.10. HIFα regulation in normoxia: Hydroxylation of HIF1a’s proline residues promotes VHL 
anchorage, which will target HIF1a for proteasomal degradation; and in hypoxic conditions: HIF1a 
promotes gene transcription. 
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accelerated angiogenesis process, yet it is known to be the result of pro-angiogenic 
factors deregulation (Kaur et al., 2004).   
 
During hypoxia, cells turn on the angiogenic switch by up-regulating the pro-
angiogenic factors such as VEGF proteins, via HIF1α and HIF2α (Keating, 2014; Liao 
& Johnson, 2007). VEGFA is a potent angiogenic factor that appears to be particularly 
important for GBM, since its over-expression and release into the extracellular matrix 
(ECM) is commonly observed (Liang et al., 2002). In addition to the transcriptional 
regulation, hypoxia seems to result in increased stability of VEGFA mRNA. Both 
mechanisms result in a thriving of VEGF signal which is particularly predominant in 
the hypoxic zone (Kaur et al., 2004). When secreted by cells, VEGFA triggers 
angiogenesis by binding to the VEGF receptors 1 (VEGFR1) and 2 (VEGFR2) on the 
endothelial cell surface. These receptors will then signal for endothelial cell 
proliferation and migration, as well for the secretion of matrix metalloproteinases 
(MMPs) (Rundhaug, 2003).  Besides these, the receptors neuropilin 1 (NRP1) and 2 
(NRP2) expressed in neural and endothelial cells surface also play a role in 
angiogenesis (Kaur et al., 2004). Although not yet well-defined what is the role in 
angiogenesis, mice with targeted disruption of these receptors show severe vascular 
defects. Plus, it is known that NRP1 functions as a receptor for a specific isoform of 
VEGFA (VEGF 165), for VEGFB and PLGF, also pro-angiogenic factors (Kaur et al., 
2004).  
During hypoxia the VEGFC and VEGFD isoforms bind to the VEGFR3 receptor 
and are mostly involved in the formation and maintenance of lymphatic vessels, known 
as the lymphangiogenesis process (Chien et al., 2009; Christiansen & Detmar, 2011). 
Despite this process being inexistent in the brain, it has been hypothesized that 
VEGFC and VEGFD cleavage forms can interact with VEGFR2 and promote 
angiogenesis (Jenny et al., 2006). However, little is known about these two VEGF 
isoforms in GBM’s hypoxia driven invasion. 
 The placenta growth factor (PLGF) is a frequently up-regulated gene in 
hypervascularized brain tumours, and its over-expression leads to tumour 
angiogenesis and growth (Kaur et al., 2004). Hence it is a pro-angiogenic protein that 
curiously shares 53% identity with VEGF. It has been shown that in the presence of 
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PLGF, VEGFA is released from VEGFR1 to bind VEGFR2, promoting endothelial cell 
proliferation. Plus, the activation of VEGFR1 by PLGF leads to inter-molecular trans-
phosphorylation of VEGFR2. PLGF functions as an enhancing factor of VEGFA signal 
in GBM (Kaur et al., 2004). 
 
1.3.3 Metabolic reprogramming 
The most important feature in cancer cells metabolic reprogramming is the shift 
from aerobic respiration to anaerobic glycolysis. This reprogrammed mechanism 
allows the use of glucose to synthesize ATP without the need for oxidative 
phosphorylation. Besides being more time-effective and least energetically demanding 
than oxidative phosphorylation anaerobic glycolysis has the bonus of generating 
‘building-blocks’ (nucleotides, lipids, etc.) and it is independent of oxygen levels which 
can vary dramatically during tumour growth. HIF activates the transcription of genes 
that encode for glucose-transporters and glycolytic enzymes, in order to maintain the 
cells energetic balance in an oxygen deprived environment (Labak et al., 2016a; Liberti 
& Locasale, 2016).  
 
HIF1α activates the transcription of GLUT1, GLUT3 and GLUT4 genes, which 
encode for glucose-transporters. These are plasma-membrane proteins that promote 
the entry of glucose from the extracellular environment into the cell. GLUT1 and 
GLUT3 proteins are significantly up-regulated in glioma cells, since a large amount of 
glucose is needed to fulfil the high metabolic demands of these cancer cells (Zhang, 
Behrooz, & Ismail-Beigi, 1999).  
 
Curiously, GLUT1 is either overexpressed or under-expressed in GBM, 
depending on the tumour area. Regularly, the overexpression zone correspond to the 
hypoxic foci, where HIF1a expression is highly predominant. In fact, GLUT1 is an 
established transcript target of HIF1a transcription factor. In addition to GLUT1, 
GLUT3 seems to have a role in GBM. First, GLUT3 is characterized as a brain tissue 
specific transporter, frequently found in neurons. Also, GLUT3 was shown to be over-
expressed in hypoxic GBM cells and to correlate with clinical outcomes. Although not 
yet proven, some studies suggest a positive feedback loop between GLUT3 and OCT4 
(a pluripotency marker), once their expressions are correlated (Labak et al., 2016).  
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Many glycolytic enzymes have been shown to be up-regulated during tumour 
hypoxia. Aldolase-A catalyzes the conversion of Fructose-1-6-bisphosphate into 
glyceraldehyde 3-phosphate. HIF1α activates the transcription of aldolase-A gene in 
response to hypoxia (Semenza et al., 1996). This protein is overexpressed in cancer 
cells not only for its importance in glycolysis, but also for being involved in vesicle 
trafficking, cell motility and epithelial to mesenchymal transition (EMT). In fact, 
aldolase A expression has been correlated with increased fibronectin and vimentin 
levels, as well as with down-regulation of E-cadherine and b-catenin levels (Lincet & 
Icard, 2015).  
 
Lactate dehydrogenase A (LDHA) is a tetrameric enzyme which catalyzes the 
conversion of NADH to NAD+ and pyruvate to lactate. One of the key steps of 
glycolysis is the conversion of GADP to D-1,3-bisphosphoglycerate (1,3BPG) and 
NAD+ (LDH enzymatic product) is a fundamental participant of this process. In hypoxic 
conditions, due to the lack of oxidative phosphorylation which would otherwise 
regenerate NAD+, LDH enzymatic function is essential. Hence its significance in 
glycogenesis (Firth, Ebert, & Ratcliffe, 1995). LDHA synthesis has been shown to be 
upregulated in GBM tumour cells, especially in pseudopalisading cells and throughout 
the hypoxic area (Talasila et al., 2016). 
 
Another mediator of glycolysis metabolism in cancer is Hexokinase 2 (HK2). 
This protein functions as a molecular switch from glycolysis to autophagy, in order to 
ensure the energy homeostasis in response to glucose deprivation (Tan & Miyamoto, 
2015). In the healthy brain, HK2 is negligently expressed. However, in GBM there are 
several transcription and growth factors, such as myc, glucagon and cAMP, that 
regulate HK2 expression. Moreover HIF1a regulates the transcription of HK2 in GBM 
hypoxia cells (Wolf et al., 2011).  
 
PFKB3 and PFKB4 are two isoenzymes from the PFK-2/FBPase-2 family which 
control the levels of fructose-2,6-biphosphate (Fru-2,6-P2). Both PFKB3 and PFKB4 
are known to be upregulated by HIF1a during hypoxia and to promote cell survival 
through metabolic adaptation to this demanding environment (Ros & Schulze, 2013). 
In fact, PFKFB3 was suggested as the isoform that most likely contributes to the 
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glycolytic activity of cancer transformed cells. However, in GBM, PFKFB4 has been 
shown to play a main role in glycolysis (Ros & Schulze, 2013).  
 
  The SLC16A3 protein (also known as MCT4) has been shown as one of the 
most upregulated genes in GBM HSR-GBM1 and JHH-GBM10 hypoxic cell lines (Lim 
et al., 2014). This protein is a well-known lactate exporter and was hypothesized as a 
regulator of proliferation, survival and growth in GBM. In fact, knock down of MCT4 
led to inhibition of proliferation, induction of apoptosis and suppression of HIF 
transcriptional activity. Associated with a poor prognosis and short survival, SLC16A3 
seems to be correlated with a lower G-CIMP (methylation phenotype) typical in the 
most aggressive types of glioma (Lim et al., 2014). 
 
1.3.4 Invasion 
In order for tumour cells to be able to invade the surrounding environment they 
need to go through epithelial to mesenchymal transition (EMT) and promote 
extracellular matrix (ECM) degradation and remodeling. EMT is a feature of epithelial 
origin tumour cells in which the epithelial phenotype is lost in order to acquire a 
mesenchymal phenotype. Cells down regulate cell-cell adhesion molecules and lose 
polarity, leading to increased migration (Gialeli, Theocharis, & Karamanos, 2011). 
Naturally, to allow hypoxic cells to evade from the primary tumour site and invade other 
sites of the brain, HIF1α targets the transcription of genes involved in these steps 
(Martin, Ye, Sanders, Lane, & Jiang, 2013). 
 
The plasmin system in cancer has been widely studied. There are two known 
forms of plasmin activators (PA): the urokinase type-PA (uPA) and the tissue PA (tPA). 
Both promote the enzymatic conversion of plasminogen into the active serine 
protease, plasmin (Zhai et al., 2011a). Capable of promoting the ECM degradation in 
a direct manner, plasmin has a key role in GBM invasion (Zhai et al., 2011a).  
 
The plasminogen receptor annexin A2-S100A10 heterotetramer (AIIt) plays a 
key role in the regulation of plasmin at the cell surface. This complex is formed by a 
dimer of the S100A10 protein (also known as p11) which binds together two molecules 
of annexin A2 (or p36) (P. A. Madureira et al., 2011). When S100A10 is not bound in 
the AIIt, it is targeted for degradation via a proteasome-dependent mechanism. 
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However, when in the AIIt, S100A10 promotes the binding of plasminogen to the 
complex, increasing its affinity with tPA, as well the catalytic reaction efficiency 
(Patricia A Madureira, O’connell, Surette, Miller, & Waisman, 2012). Indeed, S100A10 
activity has been linked to 50% of cellular plasmin generation (Patricia A Madureira et 
al., 2012). Plus, S100A10 expression is widely induced by several factors known to 
be overactivated in GBM, such as EGFR (Madureira P, O’Connell P, Surette A, et. al. 
2012). 
 
 Studies have shown that annexin A2 knockdown leads to a decrease in the 
migration ability of GBM cells. Curiously, annexin A2 was reported as significantly 
more expressed in primary GBMs than in secondary tumours. This is due to a higher 
tumour methylation phenotype of secondary GBMs in which annexin A2 promotor is 
generally methylated, therefore inactivated (Kling et al., 2016). Consequently, annexin 
A2 expression often correlates with tumour grade. Indeed, patients with higher 
annexin A2 expression have a lower Overall Survival and Progression Free Survival 
than those with a lower expression (Maule et al., 2016). Due to its role in cancer, 
annexin A2 has become a protein of interest for GBM target therapy (Zhai et al., 2011). 
Overall, the AIIt heterotetramer leads to an increase in plasmin generation and 
therefore contributes to the breakdown of the basement membrane and ECM, crucial 
for tumour invasion (Madureira P, O’Connell P, Surette A, et. al. 2012). 
 
Another plasminogen activation complex is the uPA system. When uPA binds 
to its receptor, the urokinase-type plasminogen receptor (uPAR), not only increases 
its enzymatic activity, but it also promotes a focal and directional proteolysis of the 
ECM. It is no surprise that uPARs are frequently co-localized with the hypoxic site 
(Mohanam et al., 1997). This system, often overexpressed in GBM, plays therefore an 
extremely important role in hypoxia induced invasion. In addition, the uPA-uPAR 
system also regulates cell motility, adhesion and  proliferation, also crucial invasion 
steps (Chandrasekar et al., 2003). Interestingly, the uPA-uPAR complex co-localizes 
with S100A10 at the cell surface (Madureira P, O’Connell P, Surette A, et. al. 2012).  
 
In addition to the direct breakdown of fibronectin, laminin and proteoglycans 
(ECM components), plasmin is also capable of activating MMPs which contribute to 
ECM degradation as well (Zhai et al., 2011a). MMPs are overexpressed in cancer 
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which leads to ECM remodeling, tumour invasion and metastasis and epithelial-
mesenchymal transition (EMT) by modification of integrins (Radisky & Radisky, 2010). 
In GBM cells the MMP-2 and MMP-9 gelatinases, are frequently over-expressed and 
released into the ECM (Fujiwara et al., 2007). A unique feature of these gelatinases is 
the degradation of type IV collagen, gelatin and fibronectin which are major 
components of the ECM (Cathcart Jillian, Pulkoski-Gross Ashleigh, & Cao Jian, 2015).  
Studies led by Li et. al. have shown that via knockdown of HIF2-α, a decrease in MMP-
2 expression was observed (N. Li, Wang, Zhang, & Zhao, 2016). In addition, MMPs 2 
and 9 were both shown to be enhanced during hypoxia in GBM (Emara & Allalunis-
Turner, 2014). Although known to be related with hypoxia, there are no references of 
gelatinases 2 and 9 expression by HIF1a.   
  
 
 
 
 
 
 
 
 
 
 
 
During hypoxia, angiogenesis, metabolic reprogramming and invasion 
pathways cope as cell survival mechanisms in response to a “life-threatening” 
environment, as illustrated in Figure 1.11. By doing this, hypoxic GBM cells not only 
survive, but gain clonal advantage through an increased malignancy phenotype. 
These cells are prompt to migrate to other parts of the brain and colonize healthy 
tissue, which creates a therapeutic challenge. In conclusion, hypoxia benefits cancer 
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Figure 1.11. Hypoxia mediated invasion in Glioblastoma: HIF1a targets gene transcription to 
induce metabolic reprograming, angiogenesis, ECM destruction and remodeling and epithelial to 
mesenchymal transition. 
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progression by activating malignancy pathways, which reflects into a bad prognosis in 
terms of treatment and patient survival.  (Monteiro et al., 2017) 
 
1.4 Study Objective 
Glioblastoma multiforme is one of the deadliest, with a median survival of 14 
months. GBM remains a therapeutic challenge due to these tumours aggressive 
phenotype and high rates of recurrence. Hence, it is essential to understand the 
molecular pathways in the core of GBM evolution. 
 
One of the main features of GBM is hypoxia. Close to the tumour necrotic core, 
the hypoxic zone is characterized by low levels of oxygen. This harsh environment not 
only prompt cells with clonal selection forces, it activates pro-survival and malignancy 
mechanisms such as the metabolic switch, invasion and angiogenesis. Hence we 
proposed to investigate the expression of genes and proteins featuring these survival 
mechanisms in GBM hypoxia.  
 
To do so, two GBM biopsy-derived cell lines (UP-029 and SEBTA-023) were 
used and cultured in hypoxic conditions for a selected set of time-points. We then 
investigated the hypoxic profile and landscape of these cells through microarrays 
performed for normoxia, six and 48 hypoxia hours of samples. We distinguished a 
panel of significant induction and validated through qRT-PCR assays. Lastly, we 
conducted protein detection assays and correlated with the previously obtained gene 
expression values.  
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2. Materials and Methods 
2.1 Ethical Statement 
The patients’ biopsies from which the cell lines used in this study were derived 
were obtained under the ethics permission within the Brain Tumour Research Centre, 
University of Portsmouth in compliance with the National Research Ethics Service 
(NRES). In addition, patients have concurred prior to surgery, to the use of biopsy 
material for purposes of research through the reading and signing of consent forms. 
This study was accepted by the ethics committees for the University of Portsmouth 
and SEBTA/BTR, reference number 11/SC/0048 of 19th June 2014. 
 
2.2 Cell Lines and Cell Culture 
The cell lines UP-029 and SEBTA-023, used in this study, were cultured at the 
University of Portsmouth and isolated via patient-derived ex-vivo GBM biopsies 
provided to the Brain Tumour Research Centre at University of Portsmouth, U.K. The 
human glioblastoma cell lines were maintained in high glucose (4500mg/l) Dulbecco’s 
modified Eagle’s medium (DMEM) (Sigma-Aldrich) supplemented with 10% Fetal 
Bovine Serum (FBS). Both cell lines were grown in a humidified incubator at 37ºC with 
an atmosphere of 5% CO2. Cells were regularly tested for mycoplasma. 
For experiments requiring cell counting, 10 μL of cells suspended in DMEM 
were mixed with 10 μL of trypan blue (Bio-Rad) and the number of live cells was 
determined using a Countess II FL Automated cell counted (ThermoFisher). For real 
hypoxia experiments the O2 levels were regulated to 1% and cells were plated in 
100mm plates with 10ml of complete DMEM medium per time point. 24 hours after 
platting, the cells were either not treated or treated (1% O2) for different time points as 
described in the results section.   
 
2.3 Western-Blotting 
Western blotting is a widely used laboratory technique that permits the 
identification of individual proteins from a complex mixture. In this technique, proteins 
are separated by their molecular weight. Once denatured by heating, proteins migrate 
in the gel through which voltage is applied. Since these molecules have negative 
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charges, they will travel in direction to the cathode (positive electrode). This procedure 
is hence called gel electrophoresis. Smaller proteins travel faster and more easily 
through the gel pores, than larger proteins. By the end of the run, larger proteins will 
be closer to the top of the gel, while the small ones will be further away (Mahmood & 
Yang, 2012). In addition to protein detection, this is a semi-quantitative method that 
provides a relative comparison of proteins levels between samples. Hence, western-
blot was used in this study to compare protein expression at different hypoxia hours.  
 
2.3.1 Preparation of cell lysates for protein extraction 
To obtain total protein extracts from both UP-029 and SEBTA-023 lines, cell 
lysates from different time points were prepared. Firstly, the medium of each plate was 
discarded and followed by a wash with approximately 2ml of Phosphate Buffered 
Saline (PBS) solution. The PBS was then removed and 200 to 300 µl of Lysis buffer 
(1x Protease Inhibitor cocktail [BIO-RAD], 2,5 mM EDTA, RIPA Buffer [PierceTM]; 
recipe in annex 1) was added to the plate. In this step, the plate was kept on ice to 
minimize the action of proteases and maintain proteins integrity as well. Also, in order 
to optimize the Lysis buffer action, with a spatula, mechanic lysis was induced by 
scrapping and spreading the solution through the plate. The follow-on solution (cell 
lysate) was then pipetted into a previously labeled and sterile 1.5 ml Eppendorf tube 
and left for 10 minutes on ice. These steps were repeated for all time-points of both 
cell-lines. After the 10 minutes incubation, the samples were centrifuged (VWR 
MiniStar silverline centrifuge) for 15 minutes at 15000 G, 4 ºC. This last step aimed to 
precipitate all non-soluble components so that the supernatant was merely the total 
protein extract. Subsequently, the supernatants were pipetted into new labelled and 
sterile Eppendorf tubes, to be kept at -80 ºC and so, preserved from degradation.  
 
2.3.2 Protein Quantification 
Afore preparing protein samples for western-blotting, the protein concentration 
of each sample was determined.  To do so, the Thermo-Scientific’s PierceTM 
Bicinchoninic acid (BCA) Protein Assay Kit was used according to the manufacturer’s 
instructions (annex 2). This assay consists on the biuret reaction: reduction of Cu2+ 
into Cu+ by protein in an alkaline medium. This is a method with high sensitivity and 
colorimetric detection selectivity of Cu+. The stoichiometric reaction involves the 
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chelation of two molecules of BCA with each Cu+, forming a purple water-soluble 
complex which exhibits a strong linear absorbance at 562 nm, directly proportional to 
protein concentrations.  
The samples were prepared in a clear 96 well plate, for the BCA assay. First, 
25 µl of each triplicate of unknown sample was added into a microplate well. Standard 
samples with known concentrations (Table 2.1) were added in triplicates in the plate 
as well, so that a calibration curve could be made. Then 200 µl of the Working reagent 
(50:1, BCA reagent A : BCA reagent B – annex 2) was pipetted into each well 
containing sample or standard solutions. Following, the plate was left in an incubator 
at 37 ºC for 30 minutes to be analyzed afterwards in a plate reader [Polar optima, 
BMG Labtech]. 
 
 
2.3.3 SDS-Page 
In order to cast SDS-Page gels, a BIO-RAD Mini-PROTEAN Tetra Cell Casting 
Module was used. The first step was the assembly of a short glass and a glass spacer 
plate in a casting frame that will hold them in place as the gel polymerizes. The sodium 
dodecyl sulphate poly-acrylamide gel (SDS-PAGE) was then prepared. The 
VIALS VOLUME OF 
DILUENT (µl) 
VOLUME AND SOURCE 
OF BSA (µl) 
FINAL BSA 
CONCENTRATION (µg/ml) 
A 0 300 of stock 2000 
B 125 375 of stock 1500 
C 325 325 of stock 1000 
D 175 175 of vial B dilution 750 
E 325 325 of vial C dilution 500 
F 325 325 of vial E dilution 250 
G 325 325 of vial F dilution 125 
H 400 100 of vial G dilution 25 
I 400 0 Blank 
Table 2.1. Dilution Scheme of Diluted Albumin (BSA) standards. All standard solutions were diluted in 
ddH2O. The Albumin standard stock solution provided with the kit was conserved at 4 ºC in 2 mg/ml 
ampules. 
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running/resolution gel was made up with the following stock solutions: 1M Tris (pH 
8.8), 30% acrylamide:bisacrylamide solution, H2O, 10% Sodium Dodecyl Sulfate 
(SDS), 25% Ammonium Persulfate (APS) and N, N, N’, N’-
Tetramethylethylenediamine (TEMED), as shown on Table 2.2.  
 
 
After adding the TEMED, the solution was mixed and pipetted into the glass 
plates. Water was swiftly added to remove any potential bubbles and provide a smooth 
surface. Once the gel was polymerized, the water was discarded and the plate dried. 
The stacking gel was then prepared using the reagents and amounts shown on Table 
2.3.       
  
 7% 12% 15% 
1M Tris ph 8.8 3ml 3ml 3ml 
30% 
Acrylamide:Bisacrylamide 
1,9 ml 3,2 ml 4 ml 
ddH2O 3 ml 1,7 ml 0,9 ml 
10% SDS 80 µl 80 µl 80 µl 
25% APS 32 µl 32 µl 32 µl 
TEMED 12 µl 12 µl 12 µl 
 1 GEL 2 GELS 3 GELS 4 GELS 5 GELS 6 GELS 
1M Tris ph 8.8 312.5 µl 625 µl 937.5 µl 1.25 ml 1.6 ml 1.9 ml 
30% Acrylamide 550 µl 825 µl 1.2 ml 1.65 ml 2.1 ml 2.5 ml 
ddH2O 2.3 ml 3.5 ml 5.2 ml 6.9 ml 8.6 ml 10.4 µl 
10% SDS 25 µl 50 µl 75 µl 100 µl 125 µl 150 µl 
25% APS 12.5 µl 25 µl 37.5 µl 50 µl 62.5 µl 75 µl 
TEMED 7.5 µl 15 µl 22.5 µl 30 µl 37.5 µl 45 µl 
Table 2.3. Stacking Gel formulation for different gel quantities, being each gel equivalent to a total 
volume of approximately 3 ml.  
Table 2.2. Running gel formulation for different acrylamide percentages, for total volume of 
approximately 8 ml (1 gel).  
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The stacking gel was pipetted into the plates immediately after adding the 
TEMED, once its polymerization is very fast and after checking that there were no air 
bubbles a comb was placed on the top until the gel was fully polymerized.  
 
In order to prepare the samples to load in the gel, fractions containing 20 μg/20 
μl of the extracted protein were mixed with 4x loading buffer [Bio-Rad] in final 
concentration of 1x. The samples were then boiled on a water bath or a Bio TDB-100 
dry block thermostat (BioSan) for 5 minutes and centrifuged for 15 seconds at 
maximum speed. Meanwhile, when the samples were heating up, the already 
polymerized gels were placed in a Mini-PROTEAN ® Tetra Vertical Electrophoresis 
Cell and covered with 1x Running buffer (25 mM Tris base, 250 mM glycine, 0.1% 
SDS). Into the first well of each gel, 3 μl of Precision Plus Protein All Blue Standards 
(BIO-RAD) was loaded and in the following wells the 20 µg protein fractions prepared. 
The cell was then connected to a power supply and the gels ran at 140V for 
approximately 1 hour.  
 
For the transfer, one sheet of nitrocellulose membrane and two sheets of thick 
blot filter paper were cut to the same size as the corresponding gel. They were then 
wetted in PierceTM 1-Step Transfer Buffer for a minimum of 15 minutes. After protein 
separation within the gel, the glass plates are separated and the gel retrieved. One 
sheet of thick blot filter paper was then placed on the Pierce™ G2 Fast Blotter cassette 
cathode, one nitrocellulose membrane was placed on top and the respective gel was 
arranged on top. One sheet of thick blot filter paper was added on top of the gel and 
any bubbles were removed with a blot roller. The anode plate was then gently pressed 
on top and the cassette slid into the control unit. The transfer then took place for 14 
minutes at the high mW setting. Once complete, the membrane was placed in Licor 
Odyssey® Blocking Buffer and incubated for 1 hour at room temperature using a 
horizontal rocker. The blocking buffer was then removed and the primary antibody 
added. The membrane was then incubated overnight at 4ºC. The primary antibody 
was removed and the membrane was then washed 4 times for 5 minutes incubations 
using TBS-T solution (20 mM Tris pH7.5, 120 mM NaCl, 0.05% Tween-20) . The TBS-
T was subsequently removed and the secondary antibody added. The membrane was 
then incubated for an hour at room temperature with shaking before removing the 
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secondary antibody. The membrane was washed using TBS-T for a further 4 times for 
5 minutes each wash. A Licor Odyssey® CLx instrument was then used to visualize 
the membranes. Analysis of the bands was performed using the Image Studio Lite 
software. 
 
2.3.4 Antibodies 
The following primary antibodies listed on Table 2.4 were used for western 
blotting:  
 
 
ANTIBODY REFERENCE 
ACTIN (C-11) SC-1615 
ALDOLASE A SC-12059 
ANXA2 SC-1924 
ANXA2 (D1/274.5) Made in house 
CAIX (H-11) SC-365900 
EGFR (A-10) SC-373746 
GADPH (FL-335) SC-25778 
GLUT1 (A-4) SC-377228 
HIF1A (H-206) SC-10790 
HIF2A SC-46691 
LDHA SC-12059 
MMP2 (8B4) SC-13595 
MMP9 (2C3) SC-21733 
NDRG1 (B-5) SC-398291 
PAI1 (C-9) SC-5297 
PDK1 (4A11F5) SC-293160 
PIGF (H-4) SC-518003 
S100A10 (4E7E10) SC-81153 
UPA (H77A10) SC-59727 
UPAR (E-3) SC-376494 
VEGFA SC-152 
VEGFC (E-6) SC-374628 
VEGFD SC-13085 
 
 
The following secondary antibodies listed on Table 2.5 used for western 
blotting:  
 
Table 2.4. List of primary antibodies used for western-blotting. All “SC” references refer to the Santa 
Cruz Biotechnology company. 
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ANTIBODY REFERENCE 
ANTI-MOUSE 926-32210 (Li-COR) 
ANTI-GOAT 926-32212 (Li-COR) 
ANTI-RABBIT 926-32211 (Li-COR) 
 
 
2.4 Polymerase Chain Reaction arrays 
Real-time Reverse-Transcription Polymerase Chain Reaction (RT-PCR) is a highly 
sensitive and reliable method of gene expression analysis that quantify simultaneously 
genes of the same sample. It allows the measurement of gene amplification by means 
of RNA reverse-transcripts (cDNAs). For this investigation, PCR assays were made to 
quantify the gene expression levels during hypoxia comparing to normoxia.  
 
2.4.1 RNA extraction  
To obtain total RNA extractions from both UP-029 and SEBTA-023 cell lines for 
the different time-points, QIAGEN’s RNeasyâ Plus Mini Kit was used according the 
manufacturer’s instructions (annex 3). First, each plate was washed with 
approximately 2 ml of Hank’s Balanced Salted Solution (HBSS) [Thermo Fisher], 
followed by an incubation with 2 ml of TrypLE™ Express [Thermo Fisher] for 2-3 
minutes at 37 ºC, to detach and suspend the cells. Next, the solutions with the 
suspended cells were pipetted into labelled 15 ml tubes with 3 ml of DMEM previously 
added to centrifuge for 5 minutes at 10 000 G. This centrifuging step meant to 
precipitate the cells in a pellet so that the supernatant with TrypLE™ Express and 
DMEM could be discarded. Right after this, 350 µl of the RTL buffer (lysis buffer 
provided with the kit) was added to each tube and lysis was mechanically instigated 
by pipetting up and down. The resultant RTL solutions were then transferred into 
gDNA Eliminator spin columns placed in previously labelled 2 ml collection tubes (all 
provided with the kit), to centrifuge for 30 seconds at 12000 G. Afterwards, the gDNA 
Eliminator spin columns were discarded and the flow-throughs saved in their 
respective columns to which 350 µl of ethanol 70% was directly added and mixed my 
pipetting up and down. Subsequently, the solutions were transferred into a RNeasy 
spin columns (delivered with the kit) placed in a new and labelled collection tubes to 
be centrifuged for 15 seconds at 12000 G. This step was repeated twice (350 µl each 
time), since the final volume of the previous step was 700µl and such volume could 
Table 2.5. List of secondary antibodies used for western-blotting.  
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not fit the column. The flow-throughs were then discarded and the columns saved in 
the same collection tubes, to be added 700 µl of the Kit’s RW1 Buffer followed by a 
centrifuged of 15 seconds at 12000 G. Similarly to the former, this step was done 
twice, adding 350 µl of RW1 each time. The flow-throughs were again discarded and 
the columns saved in the same collection tubes so that 500 µl of the kit’s RPE buffer 
could be added this time. The columns (in the respective tubes) were again centrifuged 
for 15 seconds at 12000 G and the flow-through discarded. This step was repeated, 
following the manufacturer’s instructions, with a centrifugation time of 2 minutes, at 
the same speed. The flow throughs were discarded. Then, replacing the RNeasy spin 
columns in new and previously labelled 1,5 ml collection tubes, 30 µl of RNase-free 
water (also provided by the kit) was directly added into each of the column’s 
membranes. This was followed by 1 minute centrifugation at 12000 G. Contrarily to 
the prior steps, this time the flow-through was saved, once it already contained the 
RNA extracts. Finally, repeating the last step, this time using 50 µl of RNase-free 
water, a total of 80µl of total RNA was extracted. This sample was then saved in the -
80 ºC to avoid RNA degradation.  
 
2.4.2 Hypoxia RT2 profiler PCR array 
The Hypoxia RT2 profiler PCR array combines the technology of RT-PCRs with 
the multigene profiling capability of microarrays. To analyze the hypoxic profile of both 
UP-029 and SEBTA-023 cell lines, Hypoxia RT2 profiler PCR array kit (QIAGEN) was 
used according to the manufacturer’s instructions (annex 4). First, the concentration 
of the RNAs extracted was quantified and tested for integrity and quality through an 
Agilent 2100 Bioanalyzer machine. To do so, a gel-dye mix (1µl dye; 65 µl filtered gel) 
was prepared following the manufacturer’s instructions (annex 5). Then, 9 µl of gel-
dye mix was loaded at the bottom of the G-marked well of the Bioanalyzer RNA-chip  
which was settled up in the priming station (annex 5). Setting the timer to 30 seconds 
and making sure that the plunger was positioned at 1 ml, the chip priming station was 
closed to pressurize. The plunger of the syringe was pressed down until held by the 
clip and remained for 30 seconds, before releasing the mechanism. After 5 seconds, 
once the plunger moved back to at least the 0.3 ml mark, the plunger was gently pulled 
back to the 1 ml position. The chip priming station was finally opened once the 
pressurizing step was completed. Next, 9 µl of the gel-dye mix was pipetted into the 
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two respectively marked wells. To load the RNA 6000 Nano Marker, 5 µl of the solution 
was pipetted into the left wells. No wells were left empty since that could interfere with 
the run analysis. The ladder aliquots were defrosted and kept on ice to avoid extensive 
warming. Before loading and to minimize secondary structures, the samples were 
heated and denatured at 70 ºC for 2 minutes. Then, 1 µl of the sample was pipetted 
into each of the 12 sample wells. Also, 1 µl of the ladder was pipetted into the well 
marked with the ladder symbol. The timer was set for 60 seconds and the chip was 
placed horizontally in the adapter of the IKA vortex mixer to vortex with a speed of 
2400 rpm. Lastly, the chip was inserted in the Agilent 2100 bioanalyzer to proceed 
with the analysis.  
 
For the RNA reverse transcription into cDNA, the reagents provided with the 
RT2 first strand kit (annex 4) were thaw and briefly centrifuged for 15 seconds to bring 
contents to the bottom of the tubes. The genomic DNA elimination mix was prepared 
according to Table 2.6. for each of the RNA samples.  
 
 
Then the mix was mixed with the samples by gently pipetting up and down, 
followed by a spin down. The samples were then incubated for 5 minutes at 42 ºC 
immediately followed by a second incubation of 1 minute on ice. The reverse-
transcription mix was then prepared as shown on Table 2.7. 
 
 
COMPONENT AMOUNT 
5x Buffer BC3 4 µl 
Control P2 1 µl 
RE3 Reverse Transcriptase Mix  2 µl 
RNase-free water 3 µl 
Total volume 10 µl 
 
COMPONENT AMOUNT 
RNA 2 µg 
Buffer GE  2 µl 
RNase-free water Up to 10 µl final volume 
Table 2.7. Reverse-transcription mix. The amounts designated in the subsequent table refer to 1 
reaction volume.   
Table 2.6. Genomic DNA elimination mix. 
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Once set, 10 µl of reverse-transcription mix was added to each tube containing 
the RNA samples and genomic DNA elimination mix. The solution was mixed by gently 
pipetting up and down, followed by an incubation at 42 ºC for 15 minutes. The reaction 
was then immediately stopped by incubating at 95 ºC for 5 minutes. Finally, each 
sample was supplemented with 91 µl of RNase-free water which was then mixed by 
pipetting up and down several times. The reaction tubes were kept on ice to proceed 
with the real-time PCR protocol.  
 
For the real-time PCR, 4 plates of 96 wells each were provided with the kit. 
Each plate had 84 wells for hypoxia-related genes, 5 housekeeping genes, 1 well 
containing a genomic DNA control, 3 wells containing reverse transcription controls 
and lastly 3 wells with positive PCR controls, as shown on Figure 2.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
The genomic DNA control (GDC) is an assay that specifically detects non-
transcribed genomic DNA. The reverse transcription control (RTC) is an assay that 
tests the efficiency of the reverse transcription reaction performed with the kit by 
detecting template synthesized from the kit’s built-in external RNA control. The 
positive PCR control (PPC) tests the efficiency of the polymerase chain reaction itself. 
The catalogue of Hypoxia related and housekeeping genes is listed on Table 2.8. 
 
 
 
Figure 2.1. RT2 Profiler PCR array plate format. Wells A1 to G12 contain the Hypoxia gene assays. Wells 
H1 to H5 contain the housekeeping genes panel (HKs), to normalize the array data. Well H6 contains a 
genomic DNA control (GDC). Wells H10 to H12 contain replicate positive PCR controls (PPC). 
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Position Gene Name 
A1 Adrenomedullin 
A2 Adenosine A2b receptor 
A3 Aldolase A, fructose-bisphosphate 
A4 Angiopoietin-like 4 
A5 Ankyrin repeat domain 37 
A6 Annexin A2 
A7 APEX nuclease (multifunctional DNA repair enzyme) 1 
A8 Aryl hydrocarbon receptor nuclear translocator 
A9 Ataxia telangiectasia and Rad3 related 
A10 Basic helix-loop-helix family, member e40 
A11 Bloom syndrome, RecQ helicase-like 
A12 BCL2/adenovirus E1B 19 kDa interacting protein 3 
B1 BCL2/ adenovirus E1B 19 kDa interacting protein 3-like 
B2 B-cell translocation gene 1, anti-proliferative 
B3 Carbonic anhydrase IX 
B4 Cyclin G2 
B5 COP9 constitutive photomorphogenic homolog subunit 5 
B6 Cathepsin A 
B7 DNA-damage-inducible transcript 4 
B8 DnaJ (Hsp40) homolog, subfamily C, member 5 
B9 Endothelin 1 
B10 Egl nine homolog 1 
B11 Egl nine homolog 2 
B12 Early growth response 1 
C1 Eukaryotic translation initiation factor 4E binding protein 1 
C2 Enolase 1 (alpha) 
C3 Erythropoietin 
C4 ERO1-like 
C5 Coagulation factor X 
C6 Coagulation factor III 
C7 FBJ murine osteosarcoma viral oncogene homolog 
C8 Glucan (1,4-alpha-), branching enzyme 1 
C9 Glucose-6-phosphate isomerase 
Table 2.8. List of Hypoxia related and housekeeping genes analyzed by the RT2 profiler array and 
respective plate position. 
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C10 Glycogen synthase 1 
C11 Hypoxia inducible factor 1, alpha subunit 
C12 Hypoxia inducible factor 1, alpha subunit inhibitor 
D1 Hypoxia inducible factor 3, alpha subunit 
D2 Hexokinase 2 
D3 Heme oxygenase 1 
D4 Hepatocyte nuclear factor 4, alpha 
D5 Immediate early response 3 
D6 Insulin-like growth factor binding protein 3 
D7 Jumonji domain containing 6 
D8 Lactate dehydrogenase A 
D9 Lectin, galactoside-binding, soluble, 3 
D10 Lysyl oxidase 
D11 Mitogen-activated protein kinase kinase kinase 1 
D12 Met proto-oncogene 
E1 Macrophage migration inhibitory factor 
E2 Matrix Metalloproteinase 9 
E3 Max interactor 1 
E4 Nicotinamide phosphoribosyltransferase 
E5 Nuclear receptor coactivator 1 
E6 N-myc downstream regulated 1 
E7 Nuclear factor kappa light polypeptide gene enhancer in B-cells 1 
E8 Nitric oxidase synthase 3 
E9 Ornithine decarboxylase 1 
E10 Prolyl 4-hydroxylase, alpha polypeptide 1 
E11 Prolyl 4-hydroxylase, beta polypeptide 
E12 Pyruvate dehydrogenase kinase, isozyme 1 
F1 Period homolog 1 
F2 6-phosphofructo-2-kinase/fructose-2,6-biphosphotase 3 
F3 6-phosphofructo-2-kinase/fructose-2,6-biphosphotase 4 
F4 Phosphofructokinase, liver 
F5 Phosphofructokinase, platelet 
F6 Phosphoglycerate mutase 1, brain 
F7 Placental growth factor 
F8 Phosphoglycerate kinase 1 
F9 Pim-1 oncogene 
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F10 Pyruvate kinase, muscle 
F11 Plasminogen activator, urokinase 
F12 Recombination signal binding protein for immunoglobulin kappa J region 
G1 RuvB-like 2 
G2 Serpin peptidase inhibitor, clade E, member 1 
G3 Solute carrier family 16, member 3 
G4 Solute carrier family 2, member 1 
G5 Solute carrier family 2, member 3 
G6 Transferrin receptor 
G7 Tumour protein 53 
G8 Triosephosphate isomerase 1 
G9 Thioredoxin interacting protein 
G10 Upstream transcription factor 2, c-fos interacting 
G11 Voltage-dependent anion channel 1 
G12 Vascular endothelial growth factor A 
H1 Actin, beta 
H2 Beta-2-microglobulin 
H3 Glyceraldehyde-3-phosphate dehydrogenase 
H4 Hypoxanthine phosphoribosyltransferase 1 
H5 Ribossomal protein, large, P0 
 
As for the real-time PCR protocol itself, first the RT2 SYBR Green mastermix 
was briefly centrifuged for 10-15 seconds to bring the contents to the bottom of the 
tube. Then, the PCR components mix was prepared in a 5 ml tube, as demonstrated 
on Table 2.9.  
 
 
Array Format Amount 
2x RT2 SYBR Green Mastermix  1350 µl 
cDNA synthesis reaction  102 µl 
RNase-free water 1248 µl 
Total volume 2700 µl 
 
The RT2 profiler PCR plate was carefully removed from its sealed bag and 25 
µl of PCR components mix was pipetted into each well of the plate. The pipette tip was 
swapped in between wells to avoid cross contaminations. Once concluded the 
Table 2.9. PCR components mix for 96 well array format. The total volume provides an excess amount 
of 300 µl to allow pipetting errors.  
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previous step, the plate was sealed with an optical adhesive film (provided by the kit). 
The plate was centrifuged at room temperature for 1 minute at 1000 G in order to 
remove any bubbles existent in the wells. Finally, the plate was inserted into the 
Lightcycler 96 SW qRT-PCR instrument (Roche) and programmed for a pre-incubation 
step of 1 cycle at 95 ºC (to activate the HotStart DNA Taq Polymerase), followed by 
45 cycles of 15 seconds at 95 ºC and one minute at 60 ºC (to perform fluorescence 
data collection). 
 
2.4.3 qRT-PCR assay 
Real-time quantitative PCR quantifies the nucleic acids in a sensitive, specific 
and reproducible way. This technique generates copies of DNA template per cycle, 
resulting in a quantitative correlation between the initial and the accumulated amounts 
(Arya et al., 2005). Eventually the polymerase reaction ceases due to inhibitors found 
with the template, reaching the end of its exponential rate.  In fact, qRT-PCR is such 
a powerful method that it is able to quantify gene expression of only 1 template (Arya 
et al., 2005).  
For this study a method of relative quantification was used. This method 
analyzes the expression of a target gene relative to a reference group (Livak & 
Schmittgen, 2001). In this study, the target genes were analyzed in hypoxia time-
points of 6, 24 and 48 hours and compared to normoxia (non-treated) samples. 
 For the quantitative real-time PCR assay (qRT-PCR), the One-step NZyRT 
supermix kit (Nzytech) was used.  Nuclease-free water, One-step NZYSpeedy qPCR 
Green master mix, as well as NZyRT mix were provided with the kit. The One-step 
NZYspeedy qPCR Green master mix contains a green intercalating dye for detection, 
stabilizers, enhancers and dNTPs. The NZyRT mix is made up of Reverse 
transcriptase and Ribonuclease inhibitor.  
 
The RNA concentration for this protocol was determined using a nanodrop 
spectrophotometer (Fisher Scientific). To prepare the mastermix for each set of 
primers, the reagents above listed and provided by the kit were mixed as shown on 
Table 2.10. 
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Once set, 9 µl of each mastermix was pipetted into the 12 wells of the respective 
gene/primers, as demonstrated in Figure 2.2.  
 
 
 
 
 
 
 
 
Next, 1 µl of RNA sample (50 ng/µl) was added to each well, swapping pipette 
tips in between wells to avoid cross contaminations. There were 4 time-points (Non-
treated, hypoxia: 6 hours, 24 hours and 48 hours) being analyzed for each gene, in 
triplicates. The RNA samples were distributed throughout the plates as shown in 
Figure 2.3. 
 
 
 
Reagent  Volume 
One-step NZYspeedy qPCR Green master mix 65 µl 
Forward primer 5,2 µl 
Reverse primer 5,2 µl 
NZyRT mix 5,2 µl 
Nuclease-free water 36,4 µl 
Total volume 117 µl 
Table 2.10. NZyRT qRT-PCR Mastermix for 13 wells volume (1 well of excess volume to cover pipetting 
errors).   
 
Master Mix 1 = Gene 1 
Master Mix 2  = Gene 2 
Master Mix 3  = Gene 3 
Figure 2.2. qRT-PCR array plate format. Demonstration of the mastermixes distribution through the plate.  
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Once all the wells had their respective mastermix and RNA sample, the plate 
was sealed with a plastic adhesive (provided with the plate) and centrifuged at 1000 
G for 1 minute. The plate was then placed into the Lightcycler 96 SW qRT-PCR 
instrument (Roche). The light cycler was programmed for a first step of pre-incubation 
and cDNA synthesis at 50ºC for 20 minutes (reverse transcription), followed by a gene 
amplification step at 95ºC for 5 minutes (polymerase activation), a denaturation step 
at 95ºC for 40 cycles of 5 seconds each and finally by an annealing/extension step of 
40 cycles of 50 seconds each at 60ºC. After each annealing cycle the gene products 
were quantified.    
 
2.4.2.1 Primers 
The following primers were used for qRT-PCR: 
GENE FORWARD PRIMER REVERSE PRIMER 
GLUT1 CTCCTGCCCTGTTGTGTATAG CAGGAGTGAGGTGGTGTATTT 
LDHA GCTGGTCATTATCACGGCTG AGCAACTTGCAGTTCGGGCTG 
VEGFA GACCTTGCCTTGCTGCTCTA CACCAGGGTCTCGATTGGATG 
VEGFC GAGGAGCAGTTACGGTCTGTG TCCTTTCCTTAGCTGACACTTGT 
VEGFD ATGGACCAGTGAAGCGATCAT GTTCCTCCAAACTAGAAGCAGC 
HIF1a ATCCATGTGACCATGAGGAAATG TCGGCTAGTTAGGGTACACTTC 
HIF2a GTGCCATGACAAACATCTTCCAG CTCGGGCTCTGTCTTCTTGCT 
UPA CAGGGCATCTCCTGTGCATG AGCCCTGCCCTGAAGTCGTTA 
UPAR GCCTTACCGAGGTTGTGTGT CATCCAGGCACTGTTCTTCA 
NT 
RNA 
Hypoxia 
6h 
RNA 
Hypoxia 
24h 
RNA 
Hypoxia 
48h 
RNA 
Figure 2.3. qRT-PCR assay plate format. Demonstration of the Non-treated (NT), hypoxia: 6 hours, 24 
hours and 48 hours RNA samples distribution throughout the plate. 
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ANXA2 CTCTACACCCCCAAGTGCAT TCAGTGCTGATGCAAGTTCC 
S100A10 AAATTCGCTGGGGATAAAGG AGCCCACTTTGCCATCTCTA 
PAI1 GGGCCATGGAACAAGGATGA CTCCTTTCCCAAGCAAGTTG 
MMP9 CGGACCAAGGATACAGTT AGTGAAGCGGTACATAGG 
MMP2 CGTCTGTCCCAGGATGACATC ATGTCAGGAGAGGCCCCATA 
ANGPTL4 GAGGTCCTTCACAGCCTGCA TGGGCCACCTTGTGGAAGAG 
BNIP3 CGCAGACACCACAAGATACCAAC GCCAGCAAATGAGAGAGCAGC 
SLC16A3 TGTGTGCGTGAACCGCTTT AAACCCAACCCCGTGATGAC 
CAIX CTTGGAAGAAATCGCTGAGG TGGAAGTAGCGGCTGAAGTC 
DDIT4 GACAGCAGCAACAGTGGCTTCG GCTGCATCAGGTTGGCACAC 
EGR1 ACCGCAGAGTCTTTTCCTGACA GGTGCAGGCTCCAGGGAAAA 
HK2 GCCTTTCCGTCCCAGCCTTTAGCC GGACTCCTGCGCCGGAGTTTCATG 
NDRG1 CTGCACCTGTTCATCAATGC AGAGAAGTGACGCTGGAACC 
PDK1 CTGTGATACGGATCAGAAACCG TCCACCAAACAATAAAGAGTGCT 
PFKB3 AGTGCAGAGGAGATGCCCTA TCAGTGTTTCCTGGAGGAGTCAGC 
TFRC ACTTGCCCAGATGTTCTCAG GTATCCCTCTAGCCATTCAGTG 
PFKB4 TTAATTTTGGAGAACAGAATGGC CGTAGCCTCATCACTGTCGC 
PIGF TGCGGCGATGAGAATCTGC AGCGAACGTGCTGAGAGAAC 
RPL0 AGACAATGTGGGCTCCAAGCAGAT GCATCATGGTGTTCTTGCCCATCA 
 
The RPLP0 gene is a housekeeping gene therefore was used to normalize the 
data of the different samples and treatments.   
 
2.4.4 Statistical analysis 
2.4.4.1 Hypoxia RT2 profiler PCR array  
There is an integrated web-based software package for the RT2 Profiler PCR 
Array system that automatically performs all ∆∆CT based fold-change calculations 
from an uploaded raw threshold cycle (CT) data. The CT values refer to the cycle from 
each the amplification of the interest gene indeed started. This value is inversely 
proportional to the number of times the gene is transcript, meaning that the lower the 
CT, the higher the expression of that gene. To calculate the ∆∆CT, this values were 
normalized with housekeeping gene CTs. The web portal 
www.SABiosciences.com/pcrarraydataanalysis.php in which the excel-format data is 
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uploaded, delivers results in formats such as the tabular, scatter, volcano, cluster-
gram and multi-group plots. This web portal also helps to correctly interpret the 
genomic DNA, reverse transcription efficiency, and positive PCR control well data.  
 
The automatic selection from HKG panel was selected to conduct the RT2 
Profiler PCR Array software-based analysis. This method automatically selects an 
optimal set of internal control / housekeeping / normalization genes for the analysis 
from the available housekeeping gene panel on the PCR Array. The software 
measures and identifies the genes with the most stable expression via a non-
normalized calculation. The CT values for these genes are then geometrically 
averaged and used for the ∆∆CT calculations. The CT cut-off was set to 35 cycles.  
 
Fold-Regulation represents fold-change results in a biologically meaningful 
way. Fold-change values greater than one indicate a positive- or an up-regulation, and 
the fold-regulation is equal to the fold-change. Fold-change values less than one 
indicate a negative or down-regulation, and the fold-regulation is the negative inverse 
of the fold-change. In order to calculate the fold-Change, the software used the 2-ΔΔCT 
formula which corresponds to: the normalized target gene expression 2-ΔCT in the test 
sample divided by the normalized gene expression 2-ΔCT in the control group (non-
treated). 
 
2.4.4.2 qRT-PCR arrays  
The results obtained from the Lightcycler 96 SW qRT-PCR instrument were 
quantified using the 2-ΔΔCT method in order to calculate the relative gene induction (fold 
change) between different samples. Each gene expression was quantified through at 
least 3 different runs, in plate triplicates (3 wells per plate). To calculate the fold change 
of 1 run for each gene, the average of the 3 Cts was calculated. Next, the average Ct 
value of the housekeeping gene was then subtracted from the average Ct of each 
genes of interest to give the ΔCt value. For each gene, the ΔCt value of the control 
group (non-treated cells) was then subtracted from the ΔCt of the hypoxia treated 
samples to give the ΔΔCt value. Finally, the formula was used to calculate the fold 
change for each gene. Once all the fold change values were determined, the average 
of the 2-ΔΔCT values of at least three independent runs was calculated for each gene.  
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The standard deviation and P-value was calculated for each gene, using the 
software MicrosoftÒ Excel Office 365 software. Explicitly, the statistical significance of 
gene expression (P-value) was evaluated for a N (nº runs) equal or higher than 3, 
using a type 2, two-tailed Student’s t-test (Type 2, Tail 2). In every case a P-value of 
less than 0.05 (*), 0.01 (**) and 0.001 (***) were considered statistically meaningful in 
3 different levels of significance. 
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3. Results 
3.1 Investigating the expression of hypoxia genes in UP-029 and SEBTA-023 
cell lines 
The QUIAGEN’s RT2 hypoxia profiler assay was used in this study since it allows 
to quantify the expression of a broad panel of genes known to be implied in this cancer 
hallmark. Through these arrays, it was possible to generate a wide number of targets 
for validation and future studies.  
 
The RT2 hypoxia arrays experiments only RNA samples with A260:A230 ratios 
greater than 1.7 and A260:A280 ratios between 1.8 and 2.0 were considered for these 
studies. Both 18S and 28S ribosomal RNA bands and peaks were examined as signs 
of RNA integrity and no RNase degradation. The RNA Integrity Number (RIN) was 
also considered as a quality control parameter and only samples with a RIN higher 
than eight were pondered. The concentration and quality of the RNAs was performed 
using an Agilent 2100 Bioanalyzer machine.   
For the RT2 array quality control, the PCR array reproducibility, the RT efficiency 
and the genomic contamination parameters were considered. The Criteria for 
Genomic DNA Contamination (GDC) was the following:  If CT(GDC) was equal or 
higher than 35, then the GDC QC reports 'Pass'. If CT(GDC) was inferior than 35, then 
the GDC QC reports 'Inquiry'. 
The results of this section are displayed in scatter plots and heat maps in Figures 
3.1 to 3.4. The scatter plot compares the normalized expression of all genes analyzed 
between the control and selected hypoxia time-point groups by plotting them against 
one another to quickly visualize large gene expression changes. The central line 
indicates unchanged gene expression. The dotted lines indicate the selected fold 
regulation threshold. Data points beyond the dotted lines in the upper left and lower 
right sections meet the selected fold regulation threshold. The Heat Map provides a 
visualization of the fold changes in expression between the selected groups (normoxia 
versus hypoxia) for every gene in the array in the context of the array layout.  The heat 
map tables, provided in annex 6 (annex 6a UP-029, annex 6b SEBTA-023), specify 
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the fold regulation data used for the map as well as the comments associated with 
each one.  
In the scatter plot, log10 (fold change) was calculated for each one of the 
analyzed genes to improve the symmetry of the data distribution and a simplified 
visualization. The same was considered for the heatmap, where the log2 (fold change) 
was calculated for each one of the analyzed genes. This last normalization was based 
in a log2 function and not a log10, to obtain a cleaner projection of the fold change in a 
larger scale. These results were then assessed by qRT-PCR analysis. 
 
3.1.1 UP-029 RT2 hypoxia array analysis 
All samples from both 6 and 48 hours time-points passed the PCR array 
reproducibility and RT2 efficiency quality control check-points. However, sample 1, 
equivalent to the Adrenomedullin (ADM) quantification well was reported as 
contaminated with genomic DNA. Due to its genomic contamination, ADM was not 
further analyzed in the qRT-PCR studies or considered in the following RT2 hypoxia 
PCR arrays result's preliminary discussion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
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Figure 3.1.  UP-029 6 hours (group 1) hypoxia time-point RT2 profiler PCR array: a. scatter plot, 
the y axis corresponds to the log10 of the 2-ΔCT 6 hours time-point group genes and the x axis to the 
log10 of the 2-ΔCT non-treated group genes. The upregulated genes match the yellow dots above the 
threshold line and the downregulated genes the blue dots underneath the threshold line. The black dots 
in between the threshold lines (dotted lines) correspond to unchanged expression genes. b. heat map, 
log2 of the 2-ΔΔCT 6 hours time-point group genes heat map table. The expression magnitude was 
estimated as high when log2 (fold change) was higher than 0 and low when log2 (fold change) was lower 
than 0. 
 
Analysis of Figure 3.1 shows that at 6 hours of hypoxia 17 genes were over-
expressed, marked in yellow above the dotted threshold line and 10 genes were 
under-expressed, marked in blue underneath the dotted threshold line, compared to 
normoxia.  
 
Three genes were highly down-regulated (Figure 3.1.b). Samples D4, G6 and 
B12, corresponding to the Hepatocyte Nuclear Factor 4a (HNF4A), Transferrin 
Receptor (TFRC) and Early Growth Response 1 (EGR1) respectively, with fold values 
below -4. While, samples A4, B3, E3, E6, F2, F3, F7 and G12 are reported as 
upregulated. These correspond to Angiopoietin Like 4 (ADM), Carbonic Anhydrase IX 
(CAIX), Max Interactor 1 (MXI1), N-myc Downstream Regulator 1 (NDRG1), 6-
phosphofructo-2kinase/fructose-2,6-biphosphate 3 and 4 (PFKB3 and PFKB4) and 
Vascular Endothelial Growth Factor A (VEGFA) genes, respectively. All fold-change 
values of these samples were relatively high (> 6). With the exception of MXI1, all 
genes were further investigated by qRT-PCR. 
 
 
 
 
B 
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Figure 3.2.  UP-029 48 hours (group 2) hypoxia time-point RT2 profiler PCR array: a. scatter plot, 
the y axis corresponds to the log10 of the 2-ΔCT 48 hours time-point group genes and the xx axis to the 
log10 of the 2-ΔCT non-treated group genes. The upregulated genes match the yellow dots above the 
threshold line and the downregulated genes the blue dots underneath the threshold line. The black dots 
in between the threshold lines (dotted lines) correspond to unchanged expression genes. b. heat map, 
log2 of the 2-ΔΔCT 6 hours time-point group genes heat map’s table. The expressions magnitude was 
estimated as high when log2 (fold change) was higher than 0 and low when log2 (fold change) was lower 
than 0. 
 
Figure 3.2.a scatter plot distinguishes 15 over-expressed genes, marked in 
yellow above the dotted threshold line and 14 under-expressed genes, marked in blue 
underneath the dotted threshold line. The 6 hours time-point data revealed a wider 
variety of under-expressed genes than this group. Yet the amount of over-expressed 
samples was approximate. Focusing these data magnitudes, it is clear that discarding 
A 
B 
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relevant outliers, the heatmap turns out to be more sensitive. In fact, it is perceptible 
that samples B3 and E2 magnitudes are extremely high and close to the limit. he B3 
gene (CAIX) was reported in the first time-point with a fold change of 11,55. In the 48 
hours time-point CAIX recounted a fold change of 30,91. Also, the E2 sample, 
correspondent to the Matrix Metalloproteinase 9 (MMP9), was not shown as over-
expressed in the first time-point. Conversely, after 48 hours, MMP9 sample 
represented a fold change of 77,17.  
 
Likewise, samples A4 (ANGPTL4), E3 (MXI1), E6 (NDRG1), F3 (PFKB4), F2 
(PFKB3) and G12 (VEGFA) were also considerably over-regulated with respective 
fold-change values of 9,19, 5,74, 5,66, 5,43, 4,66 and 5,13. These gene samples had, 
however, lower fold changes at 48 hours, compared to 6 hours of hypoxia.  
 
Samples D4, F11, G2 and G7 were shown in Figure 3.2.b as under-expressed. 
These correspond respectively to the Hepatocyte nuclear factor 4 alpha (HNF4A), 
Plasminogen Activator Urokinase (PLAU), Serpin Peptidase Inhibitor Clade E 
(SERPINE1) and Tumour Protein 53 (TP53). HNF4A and PLAU genes showed the 
most prominent magnitudes within the under-expressed samples with fold changes     
-14,52 and -13,18 correspondingly.  SERPINE1 and TP53 also recounted significant 
fold changes of -5,66 and -6,87. Curiously, SERPINE1 and TP53 were not under-
expressed in the 6 hours time-point. Both HNF4A and PLAU, although detected as 
down-regulated in the earliest time-point (with fold changes of -6,68 and -2,22), were 
unchanged at 48 hours. 
 
3.1.2 SEBTA-023 RT2 hypoxia array analysis 
All SEBTA-023 samples from both 6 and 48 hours time-points passed the PCR 
array reproducibility and RT efficiency quality and Genomic DNA contamination 
control check-points.  
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Figure 3.3.  SEBTA-023 6 hours (group 1) hypoxia time-point RT2 profiler PCR array: a. scatter 
plot, the y axis corresponds to the log10 of the 2-ΔCT 6 hours time-point group genes and the x axis to 
the log10 of the 2-ΔCT non-treated group genes. The upregulated genes match the yellow dots above the 
threshold line and the downregulated genes the blue dots underneath the threshold line. The black dots 
in between the threshold lines (dotted lines) correspond to unchanged expression genes. b. heat map, 
log2 of the 2-ΔΔCT 6 hours time-point group genes heat map’s table. The expressions magnitude was 
estimated as high when log2 (fold change) was higher than 0 and low when log2 (fold change) was lower 
than 0. 
 
Figure 3.3. shows 15 over-expressed genes, marked in yellow above the dotted 
threshold line and 6 under-expressed genes, marked in blue underneath the dotted 
threshold line.  
 
The heatmap (Figure 3.3.b) shows that the genes ANGPTL4 (A4), CAIX (B3), 
DNA-Damage-Inducible Transcript 4 or DDIT4 (B7), Hexokinase 2 or HK2 (D2), 
NDRG1 (E6) and PFKB4 (F3) were highly expressed with values between five and 
A 
B 
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eight fold. The B3 sample corresponds to the gene with the highest magnitude and, 
therefore, fold change (15,67).  
 
Figure 3.3.b reported three samples meaningfully under-expressions. These 
samples were C3, D4, and G6 correspondent to the genes Erythropoietin (EPO), 
HNF4A and TFRC.  The HNF4A gene had the highest magnitude and the lowest fold 
change value of -54,57. While EPO and TFRC had correspondent fold-changes of -
4,17 and -4,53. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.  SEBTA-023 48 hours (group 2) hypoxia time-point RT2 profiler PCR array: a. scatter 
plot, the y axis corresponds to the log10 of the 2-ΔCT 48 hours time-point group genes and the x axis to 
the log10 of the 2-ΔCT non-treated group genes. The upregulated genes match the yellow dots above the 
threshold line and the downregulated genes the blue dots underneath the threshold line. The black dots 
in between the threshold lines (dotted lines) correspond to unchanged expression genes. b. heat map, 
log2 of the 2-ΔΔCT 6 hours time-point group genes heat map’s table. The expressions magnitude was 
estimated as high when log2 (fold change) was higher than 0 and low when log2 (fold change) was lower 
than 0. 
A 
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The scatter plot exhibited in Figure 3.4.a confirms 21 over-expressed genes, 
marked in yellow above the dotted threshold line and seven under-expressed genes, 
marked in blue underneath the dotted threshold line.  
 
Figure 3.4.b heatmap distinguishes at least eight samples with relatively 
noteworthy magnitudes. From these, CAIX (B3) and NDRG1 (E6) are highly 
expressed. These genes respective fold changes were 116,97 and 30,48. Curiously, 
both genes were detected within the 6 hours time-point group with significant 
magnitudes and meaningful fold changes of 15,67 and 7,26 correspondingly.  
 
The samples ANGPTL4 (A4), DDIT4 (B7), HK2 (D2), Pyruvate Dehydrogenase 
Kinase 1 or PDK1 (E12), and VEGFA (G12) were also up-regulated. These genes 
fold-change values were 3,78, 6,28, 4,63, 3,68 and 4,23 fold, respectively. Except B7, 
that had a 0,17 lower fold-change in the 6 hours group, all other genes expression 
increased approximately 2 fold at 48 hours of hypoxia.  In addition to these data, the 
HNF4A (D4) gene was meaningfully under-expressed, with a fold change of -4,06.  
 
3.2 UP-029 and SEBTA-023 qRT-PCR arrays 
The following qRT-PCR arrays were made in order to quantify and validate the 
expression of genes distinguished in the RT2 profiler array. Each sample was ran at 
least 3 times, in order to increase significance of results. 
 
Like the quality control parameters for the RT2 array protocol, only RNA samples 
with the A260:A230 ratio greater than 1.7 and the A260:A280 ratio between 1.8 and 2.0 
were considered as good quality to use in these experiments. 
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3.2.1 Hypoxia Inducible Factors 1a and 2a expression in GBM  
 
 
Figure 3.5. UP-029 qRT-PCR assay: a. HIF1a fold-change average; b. HIF2a fold-change average; 6 
hours hypoxia time-point (orange), 24 hours hypoxia time-point (yellow) and 48 hours hypoxia time-
point (green). Fold changes and significance levels are relative to the normoxia control (Fold-change = 
1). P-values calculated with student t-test (Type 2, Tail 2) for significance levels of 0.05 (*), 0.01 (**) 
and 0.001 (***). 
 
HIF1a expression in UP-029 cells was slightly up-regulated during hypoxia, as 
shown in Figure 3.5.a. However, these results were not significant (p-value > 0,05). 
Interestingly, the fold change of this gene at 24 hours was lower than both 6 and 48 
hours.  
 
Conversely to HIF1a, HIF2a expression in UP-029 cells was significant, as 
pictured in Figure 3.5.b. The highest over-expressions were detected in the 24 and 48 
hours analysis, approximately 7 fold. Although up-regulated in the 6 hours analysis, 
HIF2a only increased 2 fold when compared to the control.  
 
Figure 3.6. SEBTA-023 qRT-PCR array: a. HIF1a fold-change average; b. HIF2a fold-change 
average; 6 hours hypoxia time-point (orange), 24 hours hypoxia time-point (yellow) and 48 hours 
hypoxia time-point (green). Fold changes and significance levels are relative to the normoxia control 
(Fold-change = 1). P-values calculated with student t-test (Type 2, Tail 2) for significance levels of 0.05 
(*), 0.01 (**) and 0.001 (***). 
  
HIF1a was not significantly over-expressed in hypoxic SEBTA-023 cells 
compared to normoxic counterparts, as disclosed in Figure 3.6.a. Although our data 
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spotted an increase in HIF1a expression parallelly to the increase of hours in hypoxia, 
these values were not statistically significant.  
 
The results in Figure 3.6.b, alike Figure 3.6.a, do not reveal any significant over-
expression of HIF2a gene in SEBTA-023 cells. Again, the fold change values were all 
lower than 2 fold, for all hypoxia time-points.  
 
3.2.2 Expression of angiogenic factors in hypoxic GBM cells 
 
 
 
Figure 3.7. UP-029 qRT-PCR array: a. VEGFA fold-change average; b. VEGFCA fold-change 
average; c. VEGFD fold-change average; d. ANGPTL4 fold-change average; e. PIGF fold-change 
average; fold change for 6 hours hypoxia (light orange), 24 hours (orange) and 48 hours (dark orange). 
Fold changes and significance levels are relative to the normoxia control (Fold-change = 1). P-values 
calculated with student t-test (Type 2, Tail 2) for significance levels of 0.05 (*), 0.01 (**) and 0.001 (***). 
 
Figure 3.7.a shows a time dependent up-regulation of VEGFA in UP-029 cells 
during hypoxia. The fold-change values were 13,39, 39,52 and 44,04 for the 6, 24 and 
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48 hours of hypoxia, respectively. The expression of VEGFC, VEGFD and ANGPTL4 
did not change under hypoxic conditions (Figures 3.7.b-d). Contrarily, PIGF was over-
expressed approximately 4 fold at both 6 and 48 hours of hypoxia (3.7.e). Still, the 
most impressive and significant result was at 24 hours hypoxia with an induction of 
approximately 8 fold. 
 
 
 
 
Figure 3.8. SEBTA023 qRT-PCR array: a. VEGFA fold-change average; b. VEGFC fold-change 
average; c. VEGFD fold-change average; d. ANGPTL4 fold-change average; e. PIGF fold-change 
average; for 6 hours hypoxia (light orange), 24 hours (orange) and 48 hours (dark orange). Fold 
changes and significance levels are relative to the normoxia control (Fold-change = 1). P-values 
calculated with student t-test (Type 2, Tail 2) for significance levels of 0.05 (*), 0.01 (**) and 0.001 (***). 
 
Figure 3.8.a refers to the VEGFA expression in the SEBTA-023 cell line. This 
gene was significantly induced, in a time-dependent manner, with fold change 
expression values of 3,18, 4,06 and 4,63 fold for the 6, 24 and 48 hours of hypoxia, 
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respectively. Expression of VEGFC, VEGFD, ANGPTL4 and PIGF fold-expressions, 
did not significantly change (3.8.b-e).  
 
3.2.3 Expression of Metabolic factors in hypoxic Glioblastoma 
 
 
 
Figure 3.9. UP0-29 qRT-PCR array:  a. Glut1 fold-change average; b. LDHA fold-change average; c. 
HK2 fold-change average; d. PDK1 fold-change average; e. PFKB3 fold-change average; f. PFKB4 
fold-change average; fold change for 6 hours hypoxia (light blue), 24 hours (blue) and 48 hours (dark 
blue). Fold changes and significance levels are relative to the normoxia control (Fold-change = 1). P-
values calculated with student t-test (Type 2, Tail 2) for significance levels of 0.05 (*), 0.01 (**) and 
0.001 (***). 
 
GLUT1 gene (Figure 3.9.a), is significantly over-expressed in UP-029 cells, with 
correspondent fold-changes of 3,95, 9,21 and 7,61 for 6, 24 and 48 hours of hypoxia. 
GLUT1 highest induction was concomitant with the 24 hours hypoxia. Likewise, 
PFKB3 highest over-expression was at 24 hours of hypoxia (Figure 3.9.e). PFKB3 
gene is significantly induced in UP-029 cells with fold-change values of 5,80, 9,91 and 
4,26 at 6, 24 and 48 hours of hypoxia. LDHA and HK2 genes were not significantly 
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induced (Figures 3.9.b and 3.9.c). Contrarily, PDK1 and PFKB4 genes, were slightly 
over-expressed (Figures 3.9.d and 3.9.f). These genes reported fold change values at 
6, 24 and 48 hours hypoxia were 3,33, 2,97 and 3,48 for PDK1 and 3,12, 2,75 and 
2,63 for PFKB4. 
 
 
 
Figure 3.10. SEBTA-023 qRT-PCR array: a. Glut1 fold-change average; b. LDHA fold-change 
average; c. HK2 fold-change average; d. PDK1 fold-change average; e. PFKB3 fold-change average; 
f. PFKB4 fold-change average; fold change for 6 hours hypoxia (light blue), 24h (blue) and 48h (dark 
blue). Fold changes and significance levels are relative to the normoxia control (Fold-change = 1). P-
values calculated with student t-test (Type 2, Tail 2) for significance levels of 0.05 (*), 0.01 (**) and 
0.001 (***). 
 
Figure 3.10.a shows that GLUT1 gene is induced in SEBTA-023 cells during 
hypoxia, with the highest expression at 24 hours. GLUT1 fold change values were 
3,66, 4,83 and 4,34 at the 6, 24 and 48 hours of hypoxia. LDHA was relatively over-
expressed in a time-dependent manner (Figure 3.10.b). Starting with 2,46 fold at 6 
hours hypoxia, this gene expression increased to 3,65 and 4,51 fold at 24 and 48 
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hours of hypoxia, respectively. Similarly, PDK1 was more over-expressed with the 
hypoxia time increment (Figure 3.10.d). PDK1 fold change values were 5,38, 6,40 and 
7,32 for 6, 24 and 48 hours of hypoxia. PFKB3 was significantly induced, especially at 
6 and 48 hours, with correspondent fold change values of 4,42 and 4,67 fold (Figures 
3.10.e). 
 
Both HK2 (Figure 3.10.c) and PFKB4 (Figure 3.10.f) genes did not report major 
fold changes. PFKB4 was only significantly induced at 6 and 48 hours with fold values 
of 3,33 and 2,59, respectively.  
 
3.2.4 Expression of Invasion factors in hypoxic Glioblastoma  
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Figure 3.11. UP-029 qRT-PCR array:  a. UPa fold-change average; b. UPaR fold-change average; c. 
Annexin2 fold-change average; d. S100A10 fold-change average; e. MMP2 fold-change average; f. 
PAI1 fold-change average; g. MMP9 fold-change average; fold change for 6 hours hypoxia (light 
yellow), 24h (yellow) and 48h (dark yellow). Fold changes and significance levels are relative to the 
normoxia control (Fold-change = 1). P-values calculated with student t-test (Type 2, Tail 2) for 
significance levels of 0.05 (*), 0.01 (**) and 0.001 (***). 
 
Figure 3.11 characterizes the expression of different invasion factors in UP-029 
cells. It is observable that most of these genes did not change significantly. In fact, 
Upa and PAI1 genes, charted in Figures 3.11.a and 3.11.f seemed to be down-
regulated in a time-dependent fashion. Upa is significantly under-expressed in UP-029 
GBM cells, with fold change values of 0,77, 0,22 and 0,26 at 6, 24 and 48 hours of 
hypoxia. The UpaR, Annexin2, S100A10 and MMP9 genes did not change 
significantly (3.11.b-d and 3.11.g). Interestingly, Figure 3.11.e, referent to MMP2, 
reported indeed a significant under-expression of 0,68 fold at 6 hours of hypoxia  and 
an over-expression of 9,95 fold at 48 hours of hypoxia.   
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Figure 3.12. SEBTA-023 qRT-PCR array: a. UPa fold-change average; b. UPaR fold-change average; 
c. Annexin2 fold-change average; d. S100A10 fold-change average; e. MMP2 fold-change average; f. 
PAI1 fold-change average; g. MMP9 fold-change average; fold change for 6 hours hypoxia (light 
yellow), 24h (yellow) and 48h (dark yellow). Fold changes and significance levels are relative to the 
normoxia control (Fold-change = 1). P-values calculated with student t-test (Type 2, Tail 2) for 
significance levels of 0.05 (*), 0.01 (**) and 0.001 (***). 
 
No invasion genes analyzed were significantly up-regulated in SEBTA-023 cells 
undergoing hypoxia (Figure 3.12). Yet, Annexin2 and MMP9 were significantly under-
expressed. Annexin2 under-regulation followed a hypoxia time-dependent fashion, 
with fold values of 0,96, 0,79 and 0,56 fold at 6, 24 and 48 hours hypoxia. Also, MMP9 
was under-expressed at 6 and 48 hours of hypoxia with fold-changes of 0,82 and 0,47 
fold.  
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3.2.5 Expression of other factors in hypoxic Glioblastoma 
 
 
 
 
Figure 3.13. UP-029 qRT-PCR array:  a. BNIP3 fold-change average; b. CAIX fold-change average; 
c. DDIT4 fold-change average; d. EGR1 fold-change average; e. NDRG1 fold-change average; f. 
SLC16A3 fold-change average; g. TFRC fold-change average; fold change for 6 hours hypoxia (light 
green), 24 hours (green) and 48 hours (dark green). Fold changes and significance levels are relative 
to the normoxia control (Fold-change = 1). P-values calculated with student t-test (Type 2, Tail 2) for 
significance levels of 0.05 (*), 0.01 (**) and 0.001 (***). 
 
Several factors were significantly induced in UP-029 cells. Figure 3.13.a shows 
BNIP3 gene significantly induced by approximately 4 fold during hypoxia. CAIX is also 
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induced with significance in a hypoxia time dependent manner, as shown in Figure 
3.13.b. This gene fold change values were 6,51, 23,93 and 42,16 at 6, 24 and 48 
hours. Figure 3.13.c shows that DDIT4 is significantly induced, especially at the 24 
hours with a fold value of 23,10.  DDIT4 over-expression values at 6 and 48 hours 
were 7,19 and 4,59, respectively. The same is verified for NDRG1 and SLC16A3 
genes in Figures 3.13.e and 3.13.f. NDRG1 pick of induction was at 24 hours with a 
fold value of 120,07, while at 6 and 48 hours was 18,49 and 76,02. SLC16A3 reported 
fold-change values of 6,00, 8,75 and 7,77 at 6, 24 and 48 hours of hypoxia. EGR1 
was not significantly over-expressed in SEBTA-023 cells (Figure 3.13.d). TFRC gene, 
however, was significantly under-regulates with fold change values of 0,51, 0,53, and 
0,29 at 6, 24 and 48 hours hypoxia (Figure 3.13.g) 
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Figure 3.14. SEBTA-023 qRT-PCR array: BNIP3 fold-change average; b. CAIX fold-change average; 
c. DDIT4 fold-change average; d. EGR1 fold-change average; e. NDRG1 fold-change average; f. 
SLC16A3 fold-change average; g. TFRC fold-change average; fold change for 6 hours hypoxia (light 
green), 24 hours (green) and 48 hours (dark green). Fold changes and significance levels are relative 
to the normoxia control (Fold-change = 1). P-values calculated with student t-test (Type 2, Tail 2) for 
significance levels of 0.05 (*), 0.01 (**) and 0.001 (***). 
  
BNIP3 is significantly over-expressed in a time-dependent fashion in SEBTA-023 
cells with fold change values of 5,18, 6,71 and 10,02 at 6, 24 and 48 hours of hypoxia 
(Figure 3.14.a). Analogously, SLC16A3 gene expression, also seemed to follow 
similar induction, with 5,27, 4,95 and 7,17 fold at 6, 24 and 48 hours of hypoxia (Figure 
3.14.f ). DDIT4 reported a significant over-expression as well, with fold values of 5,75, 
2,58 and 3,99 during hypoxia (Figure 3.14.c). CAIX and NDRG1 genes were highly 
over-expressed with significance in this cell line (Figures 3.14.b and 3.14.e). Both 
genes expression increased during hypoxia in a time-dependent manner. Indeed, at 
6, 24 and 48 hours CAIX gene reported induction values of 4,93,18,83 and 50,19 fold, 
and NDRG1 4,29, 3,89 and 22,20 fold. EGR1 gene was not over-expressed with 
significance in SEBTA-023 cells (Figure 3.14.d). TFRC was significantly under-
regulated in this cell-line, with fold-values of 0,51, 0,53 and 0,29 fold at 6, 24 and 48 
hours of hypoxia (Figure 3.14.g). 
 
3.3 Protein expression analysis 
 
Following the gene expression analysis, western-blot assays were performed in 
order to investigate how the differentially gene expressions were affecting protein 
expression. 
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Figure 3.15. UP-029 and SEBTA-023 western-blots for Non-treated cells (NT) and 1, 2, 3, 6, 24 and 
48 hours real hypoxia treatment. GAPDH blot for loading control. 
 
Figure 3.15 reports the western-blot analysis made for HIF1a, EGFR, CAIX, 
UpaR, VEGFC, S100A10 and GAPDH proteins. The GAPDH blot in this analysis was 
performed as a loading control, to assure the equal loading of protein in each well of 
the eletrophoresis gel. This is indeed validated by the similar intensity of the bands 
pictured. 
 
HIF1a blot was performed in order to validate the hypoxia treatment apllied to 
the cell lines. Yet, it is visible that the correspondent bands are quite fade. This may 
be the result of an inefficiency in the protein extraction protocol done outside the 
hypoxic chamber, since HIF1a protein is rapidily degradated in normoxia. This fact 
may have affected the interpretation of the protein transdution levels.  
 
The CAIX blot was implemented, since the corresponding gene was reported 
as extremelly upregulated in the qRT-PCR analysis. EGFR protein detection was 
included in this section, since it is commonly up-regulated in GBM. Curiously, EGFR 
protein was not detected in the UP-029 samples. Yet, it was observed in the SEBTA-
023 samples, inclusively in normoxia (NT). Additionaly, CAIX was also detecatable at 
6, 24 and 48 hours in both cell lines. The expression of this protein seemed to increase 
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in a time-depend manner. Moreover, SEBTA-023 cell line had a higher protein signal 
than UP-029, during hypoxia. 
 
Although UpaR, VEGFC and S100A10 proteins did not correspond to highly 
over-expressed genes in both cell lines, blots for these proteins were performed. The 
UpaR protein was detectable in both UP-029 and SEBTA-023 in all samples 
(inclusevely normoxia). However, SEBTA-023 showed an higher expression of this 
protein than UP-029. Similiarly, S100A10 protein was detectable in both cell lines. In 
SEBTA-023, S100A10 was extremely expressed at 1, 2, 3 and 6 hours of hypoxia. In 
UP-029 cell line, S100A10 was only detected in the 2, 3 and 48 hours of hypoxia, in a 
much lower level of expression. Curiously, VEGFC protein was fairly detectable in both 
UP-029 and SEBTA-023 cells in normoxia and its detection was slightly reduced 
concomitantly with the increment in time of hypoxia.  
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4.  Discussion 
4.1 Hypoxia gene profile of the UP-029 and SEBTA-023 Glioblastoma cell 
lines 
 Through the RT2 Hypoxia Profiler PCR array, the UP-029 and SEBTA-023 cell 
lines were analyzed for their hypoxic response panorama. The expression values were 
quantified for two different experimental groups (hypoxia 6 hours and hypoxia 48 
hours) and then plotted against the respective non-treated control, as seen in Figures 
3.1-3.4.  
 
 Overall, UP-029 cells were slightly more affected by the hypoxia treatments than 
SEBTA-023, once the first had a total of 56 differentially regulated genes while 
SEBTA-023 had 49. Summing both time-points, the UP-029 cell line had more 
differentially expressed genes than SEBTA-023, with a total of 24 repressed genes 
against 13.  Despite this, SEBTA-023 reported more over-expressed genes (36 total) 
than the UP-029 cell line (32 total). For the graphical construction a cut off of two was 
used, however for the data interpretation only genes above 4 fold for over-expressed 
and -4 fold for under-expressed were considered, as to highlight the categorically 
evocative values.  
 
 Focusing in the UP-029 data, the number of induced genes at 6 and 48 hours of 
hypoxia was approximate, with 17 and 15 over-expressed genes respectively.  
Accordingly, the analysis of Figures 3.1.b and 3.2.b both time-points disclosed eight 
noteworthy over-expressed genes, with fold-change values above four fold. In the first 
experimental cohort, ANGPTL4, CAIX, MXI1, PFKB3, PFKB4, NDRG1 and PIGF 
genes were substantially induced. With the exception of PIGF, all these genes 
maintained over-expressed in the 48 hours time-point. Plus, in this later time-set we 
detected an over-expression of MMP9’s gene, which was not reported at 6 hours of 
hypoxia.  
 
 Still in the UP-029 hypoxia time-point cohorts, it was clear an elevated gene 
repression in the 48 hours group. Comparing both time-course sets, 48 hours hypoxia 
reported 14 under-expressed genes, while at six hour’s showed only eight (excluding 
the outlier). In the first data set, the TFRC, HNF4A and EGR1, genes were identified 
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as meaningfully under-regulated. From these, only TFRC gene was repressed in the 
48 hours time-point. In addition to these, PLAU, TP53, SERPINE1, EGLN2 (Egl nine 
homolog two), LOX (Lysil Oxidase), HPRT (Hypoxanthine Phosphoribosyltransferase 
one), F3 (Coagulation Factor III), MET (Hepatocyte Growth Factor Receptor), IER2 
(Immediate Early Response two), USF2 (Upstream Transcription Factor two), NFKB1 
and HMOX1 (Heme Oxygenase one) were also down-regulated in the 48 hours 
hypoxia group.  
 
 In the SEBTA-023 hypoxia profiling data from Figures 3.3 and 3.4, it is noticeable 
an inferior number of over-expressed genes in the 6 hours cohort (15) than in the 48 
hours (21). Observing the heatmaps data from Figures 3.3.b and 3.4.b, the previous 
number of genes considered indeed meaningful reduced drastically to 6  and 8 in the 
6 and 48 hours time-points. At 6 hours of hypoxia CAIX, ANGPTL4, NDRG1, PFKB4, 
HK2 and DDIT4 genes were significantly over-expressed. All these were again 
reported as induced in the 48 hours cohort with addition of PDK1 and VEGFA. 
 
 Hypoxia did not seem to have a broad repression influence in SEBTA-023 cell 
line. In fact, the sum of the two time-point analysis only reckoned a total of three 
meaningfully repressed genes. In the 6 hours time-point, HNF4A, TFRC and EGR1 
were repressed below minus four fold. Curiously, HNF4A reported -54,57 fold 
expression in the 6 hours cohort and was the only gene with a meaningful fold change 
in the 48 hours group.  
 
 Gathering these UP-029 and SEBTA-023 enquiries, the genes ANGPTL4, 
NDRG1, CAIX, PFKB4 and VEGFA appear to be the most relevant induced genes. As 
for the repressed factors, both cell lines under-expressed the HNF4A and TFRC 
genes. Overall these induced and repressed genes seemed to be key factors in these 
cell lines hypoxia response and were further studied through qRT-PCR analysis, 
conjointly with other cell-line specific induced and repressed factors.  
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4.2 Validation of hypoxia differentially expressed genes in UP-029 and 
SEBTA-023 Glioblastoma cell lines  
 By means of qRT-PCR assays, an effort was made to validate common and 
specific differentially expressed genes in UP-029 and SEBTA-023 cell lines. To do so, 
each gene’s PCR analysis was performed at least three times (n > 3).  
 
4.2.1 Hypoxia Inducible Factors 1a and 2a expression in SEBTA-023 
and UP-029 Glioblastoma cell lines 
The major hypoxia regulators HIF1a and HIF2a were firstly investigated in order 
to evaluate how hypoxic response was induced in the studied time-points.  
 
HIF1a is known and described in the literature as a main driver of the hypoxia 
adaptive response (Monteiro et al., 2017). The RT2 profiler microarray reported HIF1a 
gene as under-regulated in UP-029 and not differentially expressed in SEBTA-023. 
This data was subsequently corroborated in both cell lines by the qRT-PCR analysis 
which did not report a significant HIF1a’s over-expression, with fold-changes below 
three fold (Figures 3.5.a and 3.6.a). Nonetheless, high fold-expression values were 
not expected, since this protein is not regulated at transcriptional level, but at protein 
level (R. H. Wenger, Kvietiko, Rolfs, Gassmann, & Marti, 1997). Furthermore, it has 
been shown that in normoxia, the levels of HIF1a mRNA are rapidly reduced (Gorlach, 
2009). The fact that the RNA extraction was performed in normoxia may have affected 
this gene’s mRNA levels.  
 
 The performed profiler array did not report any over- or under- expression of 
HIF2a gene in both cell lines during hypoxia. This is not a startling outcome since 
HIF2a, which is selectively expressed, is not as key in GBM hypoxic response as 
HIF1a (Monteiro et al., 2017). Moreover, it has been shown that HIF2a is preferentially 
expressed in Glioblastoma stem cells (GSCs) (Z. Li et al., 2009). Intriguingly, the CD44 
stem cell marker was disclosed to interact specifically with HIF2a gene in order to 
stabilize its transcripts in both hypoxia and normoxia environments (Johansson et al., 
2017). Through the qRT-PCR analysis, it was demonstrated that HIF2a gene was 
indeed up-regulated in UP-029 cells during hypoxia (Figures 3.5.b and 3.6.b). The 
SEBTA-023 cell line did not report any significant expression increment in HIF2a, with 
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its highest fold-change being 1,42 fold. Notwithstanding, the UP-029 cell line reported 
significantly high fold-change values for the 6 and 48 hours hypoxia time-points. It 
would be interesting to investigate if this cell-line expresses stem-markers such as 
CD44 to elucidate whether this cell line was originated from GSCs. 
 
4.2.2 Angiogenic factors expression in SEBTA-023 and UP-029 
Glioblastoma cell lines 
In this section, we will analyze the expression of angiogenic factors in both UP-
029 and SEBTA-023 cell lines. In this cohort, we verified the expression ANGPTL4 
and VEGFA genes previously distinguished in the RT2 array. In addition, PIGF results 
are also reviewed in this segment due to its relevant results in the UP-029 qRT-PCR.  
 
VEGFA reported as induced in both cell lines qRT-PCR (Figures 3.7.a and 
3.8.a). Yet, in the UP-029 cell line VEGFA did not report such a high over-expression 
in the RT2 array as in the qRT-PCR. Moreover, while in the RT2 array the fold-
expression decreased at 48 hours of hypoxia, in the qRT-PCR it was almost triplicated 
in a time-dependent fashion. The fact that UP-029 broadly over-expressed VEGFA 
more than the SEBTA-023 cell line, hints for a more aggressive phenotype (Chen et 
al., 2015). In the other hand, this observation may also suggest that this tumour cell 
line had origin in an astrocytoma precursor. Astrocytes naturally have VEGFA 
upregulated and in cancer this induction is even farther enhanced (Stefanik, 2013).  
 
The ANGPTL4 gene codes for a protein that has been implicated in GBM 
progression through the activation of Erk1/2 kinase (Brunckhorst, Wang, Lu, & Yu, 
2010). Furthermore, ANGPTL4 was recently reported as induced during GBM hypoxia 
(Beig et al., 2018). Agreeably with the literature, this factor was indeed induced, 
especially in the first 6 hours of hypoxia in the RT2 hypoxia profiler array. Yet, the 
Figures 3.7.d and 3.8.d qRT-PCR analysis did not confirm the magnitude of the 
microarrays fold-inductions. Oppositely, the fold-change values were below the 
designated cut-off of relevance (2 fold) in both studied cell-lines. ANGPTL4’s induction 
has been associated with chronic hypoxia (Olbryt et al., 2014). Therefore, a possible 
explanation for the fact that ANGPTL4 was not highly over-expressed in the qRT-
PCRs may be that 48 hours was not enough for a fully chronic response.  
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PIGF was not meaningfully over-expressed in the SEBTA-023 RT2 profiler and 
qRT-PCRs arrays. Yet, in the UP-029 cell line PIGF was significantly induced in the 
six and 24 hours time-points. In fact, PIGF highest expression in the qRT-PCR 
analysis occurred at 24 hours of hypoxia and in the microarray analysis was only 
reported in the 6 hours cohort. Curiously, PIGF was demonstrated to regulate HIF1a 
transcription in epithelial cells (Patel & Kalra, 2010).  
 
The PIGF protein is known to enhance VEGFA mediated signaling and 
increase angiogenesis in GBM during hypoxia (Kaur et al., 2004). As denoted above, 
VEGFA was highly induced in the UP-029 cell line as well. The fact that both of these 
angiogenic factors are expressively induced not only suggests a synergist role 
between factors. 
   
4.2.3 Expression of metabolic factors in SEBTA-023 and UP-029 
Glioblastoma cell lines 
This section will discuss and analyze the expression of metabolic factors in both 
UP-029 and SEBTA-023 cell lines.  
 
In both studied cell lines, GLUT1 and LDHA genes were not reported as 
differentially expressed in the RT2 profiler array. However, both genes were reported 
as relevantly over-expressed in the qRT-PCRs, as shown in Figures 3.9.a and 3.10.a 
(GLUT1) and 3.9.b and 3.10.b (LDHA). In the UP-029 cell line both genes had their 
fold-induction peak at the 24 hours of hypoxia. Whereas in the SEBTA-023 cells the 
fold change of GLUT1 and LDHA were higher at 24 and 48 hours of hypoxia 
respectively. Interestingly, GLUT1 has been shown to be up-regulated in GSCs 
through VEGFA (Labak et al., 2016b). Studies regarding this interaction in GBM 
should be considered in the future.  
 
The PDK1 was fairly induced and maintained through the hypoxic time course in 
both cell lines, as shown in Figures 3.9.d and 3.10.d. The protein encoded by this gene 
is key in the ATP synthesis via glycolysis and is commonly up-regulated in cancer due 
to the tumour cells energy uptake (Labak et al., 2016b).  
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Similarly, to PDK1, PFKB3 and PFKB4 are central effectors of the glycolytic 
metabolism. In addition, PFKB4 has been found to be required in GSCs (Chesney et 
al., 2014). The fact that PFKB4 was so noteworthy induced in both cell lines and 
detected in both arrays, hints once again for a stem-like phenotype. Interestingly, 
PFKB3 was described in the literature as less induced than PFKB4 (Chesney et al., 
2014). This was indeed seen in Figures 3.10.e and f which correspond to the SEBTA-
023 cell line. Yet, in Figures 3.10.e and f the opposite was reported, being PFKB3 
significantly more expressed than PFKB4 in UP-029 cells. Interestingly, PFKB3 was 
described as a resistance factor to radiotherapy (Gustafsson et al., 2018). According 
to the available information, the patients from whom this studies’ cell lines were 
derived went through the standard therapy (which includes radiotherapy), previously 
to the biopsy extraction. The fact that only UP-029 up-regulated PFKB3 instead of 
PFKB4, may infer for a more aggressive phenotype and an adaptive resistance 
mechanism of this cell line.  
 
4.2.4 Expression of invasion factors in SEBTA-023 and UP-029 
Glioblastoma cell lines 
This section will disclose the differentially expression of invasion factors in both 
UP-029 and SEBTA-023 cell lines. Unexpectedly, none of the invasion genes 
analyzed through both cell lines qRT-PCR assays, were indeed significantly over-
expressed. Furthermore, only MMP9 was reported as over-expressed in the RT2 
profiler array. 
  
Both UPA and UPAR genes are normally over-expressed in GBM normoxia 
(Brat et al., 2004). Therefore, it was not expected great fold-increments of these 
genes. Also, AnnexinA2 reported low fold-change values, however we extrapolate that 
it might be an later event in hypoxic response. Furthermore, S100A10, which was not 
significantly over-expressed, is ubiquitously expressed and regulated at protein levels 
(Madureira P, O’Connell P, Surette A, et. al. 2012).  
 
PAI1 is an inhibitor of the tPA and uPA plasminogen activation systems and is 
described as up-regulated during hypoxia (Kaur et al., 2005). However, PAI1 was not 
significantly over-expressed in the qRT-PCR assays of both cell lines.  
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Since MMP2 and MMP9 are known to be regulated by HIF2α, an increase of 
these gene’s expression was not expected in the SEBTA-023 cell line (Li N, Whang 
H, Zhang J, Zhao E, 2016). Conversely, the UP-029 reported an over-expression of 
HIF2a gene. Indeed, MMP9 was over-expressed in the 48 hours cohort of the RT2 
array. Yet, MMP2 was not relevantly induced in the qRT-PCR. Curiously, MMP9 is 
reported in the literature as more induced than MMP2 in primary GBM’s (Choe et al., 
2002).  
 
4.2.5 Expression of other hypoxia related genes in SEBTA-023 and 
UP-029 Glioblastoma cell lines 
This last gene expression analysis section will focus in varied factors, non-
specifically integrated in a hypoxic feature such as the above nominated.   
 
 The BNIP3 gene codes for a pro-apoptotic protein of the Bcl-2 family. In normal 
conditions its expression is low in brain. In GBM, BNIP3 expression in highly induced 
during hypoxia. Nevertheless, BNIP3 protein has been reported to be sequestered in 
the nucleus of GBM cells to block their ability of association with the mitochondria and 
inducing cellular death (Burton, Henson, Baijal, Eisenstat, & Gibson, 2006). 
Accordingly, BNIP3 was indeed reported as over-expressed in the RT2 profiler and 
qRT-PCR arrays.  
 
 The DDIT4 gene codes for a protein which functions as an mTOR inhibitor. Yet, 
in GBM over-expression of this protein is associated with poor prognosis (Pinto et al., 
2017). DDIT4 gene was indeed already reported as up-regulated during hypoxia in 
GBM (Mongiardi et al., 2016). However, the mechanisms through which DDIT4 
promotes GBM are poorly understood. Although relatively upregulated in the SEBTA-
023 cell line, the most prominent DDIT4 induction was reported in UP-029 at 6 hours 
of hypoxia. This result validates DDIT4 as a hypoxia-induced factor in GBM.  
 
 SLC16A3 has been reported as a poor outcome marker and as over-expressed 
in astrocytes and GSCs during hypoxia. High expression levels of this gene were 
found especially in the non C-GIMP than any other subtype of GBM. Curiously, the 
protein coded by this gene is known to involved in the glycolytic cycle in  non-
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neoplastic neural stem-cells (Lim et al., 2014). The significant over-expression of this 
gene in both cell lines suggests an non C-GIMP phenotype, as well as astroglial 
characteristics.  
 
TFRC protein functions as an iron transporter and is normally up-regulated in 
cancer stem cells (Schonberg et al., 2015). Curiously, this gene was reported with 
under-expression values in the RT2 profiler array. Accordingly, TFRC was also under-
expressed in its qRT-PCRs analysis. Yet, there is no reference in the literature of the 
repression of this gene in GBM hypoxia, pointing it out as a novel marker in need of 
further studies.  
 
Both NDRG1 and CAIX genes were the leading over-expressed factors of the 
present section. In fact, both these genes are described in GBM hypoxia literature.  
CAIX gene is related with the acid/base homeostasis (Monteiro et al., 2017).  Indeed, 
this gene is a known marker of previous or current chronic hypoxia (Harun M. Said et 
al., 2008). Concurrent with the literature, CAIX was indeed over-expressed in the RT2 
profiler and qRT-PCR arrays and its inducement was directly proportional to the 
increment of hypoxia hours in both cell lines. Additionally, CAIX is a known biomarker 
of chemo- and radiotherapy resistance (Monteiro et al., 2017). Knowing that the 
patients from whom the cell-lines were derived went through standard therapy, we 
may extrapolate that the high levels of CAIX as early as 6 hours of hypoxia may be 
derived from an adaptive resistance. Also, NDRG1 seems to have a meaningful role 
as a tumour suppressor in cancer and is transcriptional regulated by HIF1a in acute 
hypoxia (Harun M. Said et al., 2008; Harun Muayad Said et al., 2017). Indeed, we 
observed significant over-expression of this gene at 24 hours in UP-029 cells with 
concomitant decrease at 48 h of hypoxia. This was previously reported in other studies 
(Harun Muayad Said et al., 2017). Nevertheless, in the SEBTA-023 cell line, the 
NDRG1 gene suffered an over-expression increment throughout the hypoxia time-
course. A possible justification for this result could be that the SEBTA-023 suffered a 
delayed acute hypoxia response.  
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4.3 Protein levels analysis in SEBTA-023 and UP-029 Glioblastoma cell lines 
 In this section we will analyze the levels of expression of proteins in both UP-
029 and SEBTA-023 GBM cell lines, during hypoxia. 
 
HIF1a expression was detectable throughout both cell line’s hypoxia time-
points. HIF1a signal was not extremely high due to the fast protein degradation. Yet, 
despite the correspondent gene fold-change values were not significant, there is an 
increase of the protein levels. Once more, it is confirmed that HIF1a is regulated not 
at transcriptional, but protein level.  
 
EGFR was added to this experiment since it is commonly up-regulated in GBM, 
especially in the primary subtype (HONGSHENG et al., 2017). Curiously, this protein 
was only detectable in SEBTA-023 samples. From these results, we query whether 
SEBTA-023 may be an primary GBM.  
 
CAIX protein signal was detected in both cell lines at 6, 24 and 48 hours of 
hypoxia. This results are in concordance with the correspondent gene expression 
values obtained through qRT-PCR. Once more, the detection of CAIX at 6 hours of 
hypoxia may be a result of an adaptive resistance mechanism. Curiously, this protein 
was more predominant in the SEBTA-023 cell line.  
 
UPAR gene was not significantly over-expressed in UP-029 and SEBTA-023 
cells during hypoxia in opposite to what was expected. However, we detected UPAR 
protein in both cell lines, especially in the SEBTA-023 samples. We extrapolate that 
the induction of the uPA system in the this specific cell line may be an later event and 
more time-points should be added to this experiment in order to verify this. 
 
VEGFC was highly detectable in both cell lines during both normoxia and 
hypoxia. Peculiarly, this protein levels seem to decrease in a time-depend manner, 
during hypoxia. However, there is no reports in the literature of this fact or VEGFC role 
in GBM hypoxia.  
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S100A10 was detectable in both cell lines. In the UP-029, protein levels could 
be seen at 2, 3 and 48 hours of hypoxia, while in SEBTA-023 it could be seen at 1, 2, 
3, 4 and 48 hours of hypoxia. This shows that S100A10 is indeed regulated at protein 
level, since it gene expression values were maintained. In addition, it demonstrates 
that the protein levels of AnnexinA2 were increased in these time-points, since without 
the bonding to annexin, S100A10  is immediately degraded.  
  
Overall, we extrapolate that the low detection of invasion proteins in these cell 
lines may be a late event. The activation of metabolic and angiogenic mechanisms 
seem to be an earlier event in the hypoxic response. Reaching the a critical stage of 
survival, in which these signaling features are not enough, cells finally activate 
invasion as a chronic response. Therefore, more time-points such as 72 and 48 hours 
of hypoxia should be added in future studies. Furthermore, the low protein signal in 
the UP-029 cells, especially in the uPAR blot, may be derived of complications in the 
protein extraction or even western-blot sample preparation protocols.  
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5. Conclusion 
 
The relevance of this research work relies especially in the poor prognosis and low 
overall-survival of GBM patients. Glioblastoma is highly characterized by a hypoxic 
phenotype which leads to invasion, angiogenesis and metabolic shift, all crucial steps 
of carcinogenesis. Understanding the molecular mechanisms underlying hypoxia in 
GBM is therefore of the highest relevance.  
 
In the present study SEBTA-023 and UP-029 biopsy-derived cell lines were used 
in order to identify and validate hypoxia-triggered factors that may be contributing to 
GBM progression and relapse. In addition, an approach to characterize the studied 
cell lines was made throughout this study. Our results distinguished several genes 
related with specific hypoxia-features, such as angiogenesis and the metabolic switch. 
This study identified, ANGPTL4, NDRG1, CAIX, PFKB4, VEGFA, PIGF, PDK1, 
PFKB3, PFKB4, BNIP3, CAIX, DDIT4, NDRG1 and SLC16A3 as genes that were up-
regulated and HNF4A and TFRC as down-regulated genes during hypoxia in GBM 
cells. Indicating that these genes might be important for hypoxia induced GBM 
pathogenesis. Moreover, revising the panel of differentially expressed genes, our data 
suggested a stem-like phenotype of the investigated cell lines. This should be 
confirmed by immune-staining with specific stem cell markers, such as CD44. 
Additionally, we detected low invasion genes and proteins expressions in both cell 
lines. We hypothesize that these factors might be regulated in response to chronic 
hypoxia. Curiously, our findings suggest PFKB3 as a possible novel resistance 
biomarker in GBM. Additionally, we hypothesize TFRC as having an important role as 
a tumour suppressor.  
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FUTURE PERSPECTIVES 
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6. Future perspectives 
 
In the future, it would be interesting to repeat this research with more GBM cellular 
types. Since GBM tumours are highly heterogeneous, elevating the number of lines in 
this study would bring more selectivity in targeting novel markers of hypoxia invasion 
from wide panels. Also, both RT2 profiler arrays and qRT-PCRs should be performed 
for a higher n, in order to increase the results significance and avoid fold regulations 
miss-interpretations. Moreover, more hypoxia time-point should be considered in order 
to fully evaluate chronic hypoxic response, especially in invasion genes and proteins. 
 
To confirm and validate the role of each one of the supposed novel markers, functional 
assays in hypoxia should be performed. Studies should be conducted in order to 
understand how standard treatment affects the expression of PFKB3. For example, 
studies regarding the detection of this protein in biopsies pre- and post-standard 
treatment, as well functional studies in GBM cell lines. In addition, TFRC knock-out 
assays should be done in order to understand the relevance of this gene’s repression.  
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8. Appendix 
8.1 Annex 1: Lysis Buffer preparation protocol 
- First, prepare a box with Ice. 
- Prepare buffer solution as established in the following table (ALWAYS keep 
the Lysis Buffer solution on ice; Don’t save any lysis buffer, always prepare a 
fresh solution for the protocol): 
 
Volume RIPA PIERCE 
buffer 
Proteases 
inhibitor 
(100x) 
MEBTA solution 
(0,5 M) 
0,5 ml 500 µl 5µl 2,5µl 
1 ml 1000 µl 10µl 5µl 
2 ml 2000 µl 20µl 10µl 
3ml 3000 µl 30µl 15µl 
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8.2 Annex 2: BCA assay protocol 
 
 
 
 
 
 
 
 
 
 
(Provided in informatic support) 
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8.3 Annex 3: QIAGEN: RneasyR Plus Mini Kit Protocol 
• Discard the media and wash with HBSS (~2ml). 
 
• Incubate for 2-3 minutes, at 37ºC with Trypsin. 
 
• Pass the cells into a 15ml tube with 3ml of growth medium. 
 
• Centrifugate for 5 min. and discard medium. 
 
• Add 350 µl of RLT Buffer (lysis buffer) to the tube and mechanically instigate 
the lysis process by pipetting. 
 
• Transfer the RLT solution with cells to the gDNA Eliminator spin column (purple) 
placed in a 2ml collection tube. 
 
• Centrifuge 30s at ³10’000 rpm (p.e. 10’500 rpm) and discard the column. SAVE 
THE FLOW-THROUGH.  
 
 
 
 
 
 
• Add 350 µl of ethanol 70% directly to the flow-through and mix it by pipetting. 
 
• Transfer all solution (~700 µl) to a RNeasy spin column (pink) placed in a 2ml 
collection tube. Close lid and centrifuge for 15s at ³10’000 rpm (p.e. 10’500 
rpm). Discard the flow-through. 
 
• Add 700 µl of RW1 Buffer to the same RNeasy spin column (pink) and 
centrifuge for 15s at ³10’000 rpm (p.e. 10’500 rpm). Discard the flow-through. 
 
✓ 
Discard  
column 
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• Add 500 µl RPE Buffer to the same RNeasy spin column (pink) and centrifuge 
for 15s at ³10’000 rpm (p.e. 10’500 rpm). Discard the flow-through. 
 
• Add 500 µl RPE Buffer to the same RNeasy spin column (pink) and centrifuge 
for 2 minutes at ³10’000 rpm (p.e. 10’500 rpm). Discard the flow-through. 
 
• Place the RNeasy spin column (pink) in a new 1,5ml collection tube (similar to 
the normal Eppendorf). Add 30-50 µl RNase-free water directly to the RNeasy 
spin column membrane.  Close the lid and centrifuge for 1 minute at ³10’000 
rpm (p.e. 10’500 rpm). SAVE THE FLOW-THROUGH. 
 
• Repeat elution with another 50 µl RNase-free water applied directly to the 
RNeasy spin column membrane. Close the lid and centrifuge for 1 minute at 
³10’000 rpm (p.e. 10’500 rpm). SAVE THE FLOW-THROUGH. 
 
•  Discard the RNeasy spin column (pink) column and save the flow-through 
(Extracted RNA solution) in the -80ºC. 
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8.4 Annex 4: RT2 array protocol 
 
 
 
 
 
 
 
 
 
 
(Provided in informatic support) 
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8.5 Annex 5: Bioanalyzer protocol 
 
 
 
 
 
 
 
 
 
 
(Provided in informatic support) 
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8.6 Annex 6: RT2 arrays reports- 
a. UP-029  
b. SEBTA-03 
 
 
 
 
 
 
 
 
(Provided in informatic support) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
